

Curriculum Vitae

Paul John Wolters, M.D.

Address: University of California, San Francisco
513 Parnassus Ave
M1090, Box 0111
San Francisco, CA 94143-0111

Phone: 415-514-2601
Cell: 415-218-1816
Fax: 415-502-6235
Email: paul.wolters@ucsf.edu

Education:

1982-1984	St. Thomas College, St. Paul MN		Biology
1984-1987	University of Minnesota, Minneapolis, MN	B.S.	Biochemistry
1988-1992	University of Minnesota, Minneapolis, MN	M.D.	Medicine
1992-1995	University of Colorado, Denver, CO	Intern/Resident	Internal Medicine
1995-1999	University of California, San Francisco, CA	Fellow	Pulmonary
1996-1999	University of California, San Francisco, CA	Fellow	Critical Care

Academic Appointments:

1999-2008	Assistant Professor, Department of Medicine, University of California, San Francisco, CA
2008-2016	Associate Professor, Department of Medicine, University of California, San Francisco, CA
2008-present	Director of Biological Research for the UCSF ILD Program
2011-present	Director of the Nina Ireland Lung Disease Program Biorepository
2011-present	Co-director of the Northern California Scleroderma Research Consortium
2013-present	Service Chief- UCSF Pulmonary Consult Service
2015-present	Pulmonary Fibrosis Foundation Care Center Network Director; UCSF site
2016-present	Professor, Department of Medicine, University of California, San Francisco, CA

License Certification:

1993	National Board of Medical Examiners
1995-present	American Board of Internal Medicine
1995-present	California State Medical License
1997-present	Pulmonary Subspecialty Board Certified
1998-present	Critical Care Medicine Subspecialty Board Certified

Honors and Awards

1994	Finalist, clinical vignette competition, 1994 ACP meeting.
1997	Foundation for Fellows in Asthma Research Award
1998	American Lung Association research training fellowship
2005	Michael S. Stulberg Outstanding Teaching Award in Pulmonary Medicine

2006-present Listed in Best Doctors in America Database
2010,11 Patients' Choice Award

Keywords/Areas of Interest:

Lung fibrosis, IPF, aging, alveolar type II cell, epithelial-mesenchymal transition, senescence, telomere, scleroderma, hypersensitivity pneumonitis, nonspecific interstitial pneumonitis.

Professional Societies

American Thoracic Society 1996-present

Editorial Services

Ad-hoc reviewer: Aging Cell; American Journal of Physiology- Lung Cell and Mol Biol; American Journal of Respiratory Cell Molecular Biology; American Journal of Respiratory and Critical Care Medicine; Arthritis & Rheumatology; BMS Medicine; Chest; European Respiratory Journal; Frontiers in Immunology; JCI-Insight; Journal of Clinical Investigation; Journal of Experimental Medicine; Journal of Biological Chemistry; Journal of Immunology; Lancet Respiratory Medicine; *Lancet Rheumatology*; Nature; New England Journal of Medicine; Respiratory Research; Science Translational Medicine; Scientific Reports; Thorax.

Other professional Activities

Advisory Boards

2016- present	Nina Ireland Program for Lung Health Executive Committee
2016	Genentech; pulmonary fibrosis advisory board meeting
2018-present	Numedii scientific advisory board
2018-present	Blade therapeutics clinical advisory board
2018	Boehringer Ingelheim; pulmonary fibrosis advisory board mtg.
2019	Gossamer Biotech; pulmonary fibrosis advisory board mtg.
2019-present	Thirona scientific advisory board
2021	Fate Therapeutics; IPF panel discussion
2021	Sanofi/Genzyme; ASMD pulmonology advisory board
2022	DSMB Annexon Biosciences

Associate Editor

2013 - 2017	BioMed Research International, Pulmonology section
2017- 2022	Thorax

Editorial Board Member

2013 - 2022	European Respiratory Journal
2011 - 2017	American Journal of Physiology- Lung Cell and Mol Biol
2013 - 2017	BioMed Research International, Pulmonology section

Conferences organized

2010 Co-chairperson, UCSF Update in Interstitial Lung Disease, San Francisco, CA
2012 Chairperson, ATS Public Advisory Roundtable, Better Breathing with the ATS
2016 Co-chairperson, UCSF Update in Interstitial Lung Disease, San Francisco, CA
2018 ICLAF program committee

Committee work

2009,13	UCSF Sleep Center search committee
2014 -2017	Respiratory Cellular Molecular Biology Program Committee, ATS
2014 -2016	Pulmonary Fibrosis Foundation Biorepository Committee.
2016- present	Pulmonary Fibrosis Foundation Registry Steering Committee
2015- present	UCSF Pulmonary Fellowship Selection Committee
2014-present	UCSF Pulmonary Fellowship Program Evaluation Committee
2019-present	UCSF PERT committee
2019	UCSF ILD Program Director search committee (chair)
2021	UCSF Bronchoscopy Director search committee

Invited Lectures and Presentations

International

2022	Visiting Professor, Peking University, Beijing China (Virtual)
2022	American Thoracic Society Meeting, San Francisco, CA
2021	Australasian Rare Lung Disease Conference 2021
2021	Visiting Professor, Peking University, Beijing China (Virtual)
2020	Telomere Dysfunction and COVID Webinar
2020	European Respiratory Society Meeting, Vienna Austria (virtual)
2019	Visiting Professor, Peking University, Beijing China
2018	Visiting Professor, Nanjing University, Nanjing China
2018	Shulan Hospital, Hangzhou China
2017	British Thoracic Society Meeting, London England
2015	7th International Wasog Conference on Diffuse Parenchymal Lung Diseases, São Paulo Brazil
2014	Scleroderma Research Foundation Webinar
2014	18 th International Colloquium on Lung Fibrosis, Mont-Tremblant Canada
2012	17 th International Colloquium on Lung Fibrosis, Modena Italy
2012	American Thoracic Society Meeting, San Francisco, CA
2010	BRU/GSK Epithelial Cells in Idiopathic Pulmonary Fibrosis workshop, Nottingham, England
2008	American Thoracic Society Meeting, Toronto Canada
2008	15 th International Colloquium on Lung Fibrosis, Myrtle Beach, NC.
2006	Update on Interstitial Lung Disease, University of Florence, Florence Italy.
2006	Visiting Professor, University of Sienna, Sienna Italy.
2006	ALAT Meeting, Cancun Mexico
2005	Mast cell signaling and function in health and disease, Eilat Isreal.
2004	13 th International Colloquium on Lung Fibrosis, Calgary Canada.

National

2022	Scleroderma Research Foundation Annual Meeting, San Francisco, CA
2021	Boehringer Ingelheim Pharmaceuticals Inc
2021	Scleroderma Research Foundation Annual Meeting, San Francisco, CA
2020	Scleroderma Research Foundation Annual Meeting, San Francisco, CA
2019	NIH Telomeres, DNA Damage, Senescence, and Lung Disease Workshop
2019	Scleroderma Apex Mtg. Chicago, Il.
2019	Scleroderma Research Foundation Annual Meeting, San Francisco, CA

2017 Pulmonary Fibrosis Foundation Meeting, Nashville TN
 2017 Scleroderma Research Foundation Annual Meeting, San Francisco, CA
 2016 Scleroderma Research Foundation Annual Meeting, San Francisco, CA
 2015 Scleroderma Research Foundation Annual Meeting, San Francisco, CA
 2014 Scleroderma Research Foundation Annual Meeting, San Francisco, CA

 2007 Keystone symposia: Mast Cells and Basophils: Host Defense and Disease
 2006 American Thoracic Society Meeting, San Diego, CA
 2005 American Thoracic Society Meeting, San Diego, CA
 2005 Pulmonary Research Conference, University of Minnesota,

Regional

2022 Pulmonary research conference, University of California, San Francisco CA
 2021 Pulmonary Grand Rounds, University of California, San Francisco, CA.
 2018 UCSF Update in Interstitial Lung Disease, San Francisco, CA
 2018 Genentech, South San Francisco, CA
 2017 Pulmonary Research Retreat, University of California, San Francisco, CA
 2017 UCSF Molecular Medicine Conference Series, San Francisco, CA
 2016 UCSF Update in Interstitial Lung Disease, San Francisco, CA
 2015 UCSF Rheumatology Grand Rounds, San Francisco, CA
 2015 UCSF Updates in Internal Medicine, San Francisco, CA
 2015 Pulmonary Research Retreat, University of California, San Francisco, CA
 2014 UCSF Update in Interstitial Lung Disease, San Francisco, CA
 2013 UCSF GEMS Demystifying Medicine Seminar, San Francisco, CA
 2012 UCSF Update in Interstitial Lung Disease, San Francisco, CA
 2012 Hospital Medicine Grand Rounds, Kaiser Permanente, Oakland, CA
 2011 Medicine Grand Rounds, Highland Hospital, Oakland, CA
 2010 Hospital Medicine Grand Rounds, Kaiser Permanente, San Francisco, CA
 2010 Medicine Grand Rounds, San Francisco VAMC, San Francisco, CA
 2010 UCSF Updates in Internal Medicine, San Francisco, CA
 2010 UCSF Update in Interstitial Lung Disease, San Francisco, CA
 2009 ILD Conference, Cal Pacific Med Center, San Francisco, CA
 2009 Medicine Grand Rounds, Highland Hospital, Oakland, CA
 2009 UCSF Updates in Internal Medicine, San Francisco, CA
 2009 Pulmonary Grand Rounds, University of California, San Francisco, CA
 2009 UCSF Demystifying Medicine Series, San Francisco, CA
 2008 UCSF Update in Internal Medicine, San Francisco, CA
 2008 UCSF Update in Interstitial Lung Disease, San Francisco, CA
 2007 Pulmonary Research Retreat, University of California, San Francisco, CA
 2006 San Francisco "Living with IPF" Patient Seminar
 2005 Updates in Internal Medicine, University of California, San Francisco, CA
 2005 Pulmonary Grand Rounds, University of California, San Francisco, CA
 2004 Pulmonary Research Retreat, University of California, San Francisco, CA
 2004 Advances in Pulmonary and Critical Care Medicine, San Francisco, CA.
 2004 Pulmonary Grand Rounds, University of California, San Francisco, CA.
 2003 Update in Pulmonary and Critical Care Medicine, Mercy Medical Center.
 Sacramento, CA.

- 2000 Pulmonary Grand Rounds, University of California, San Francisco, CA.
- 1998 American Lung Association: California Chapter
- 1998 Kaiser Permanente Update on Critical Care Medicine. Monterey California
- 1996 Pulmonary Grand Rounds, University of California, San Francisco, CA.
- 1995 Pulmonary Grand Rounds, University of California, San Francisco, CA.

Government and Other Professional Service

Grant Study Sections

- 2004: NIH study section ZHL1 CSR-P: Special Emphasis Panel for RFA HL-04-029.
- 2006: Ad hoc reviewer of NSF Grants
- 2007: Ad hoc reviewer for Medical Research of Scotland Grants
- 2009: Reviewer for the Raine Medical Research Foundation Grants, Australia
- 2011: Reviewer for the Fondazione Cariplo Scientific Research in Biomedicine
- 2012: NIH study section ZRG1 CVRS-G: Lung Injury Repair, and Remodeling Study Section
- 2012: Reviewer for Biotechnology and Biological Sciences Research Council research proposals, United Kingdom
- 2012: Reviewer for the Fondazione Cariplo Scientific Research in Biomedicine
- 2012-present: UCSF RAP Molecular Medicine Grant Review Committee
- 2013: NIH study section ZRG1 CVRS-G: Lung Injury, Repair, and Remodeling Study Section
- 2013: Australian Government National Health and Medical Research Council grants
- 2014: Penn Center for Orphan Disease Research and Therapy grants
- 2015: NIH study section ZAI1 TC-I (M1): NIAID Investigator Initiated Program Project Applications (P01)
- 2015: DOD FY15 Peer Reviewed Medical Research Program (PRMRP)
- 2015: Medical Research Foundation
- 2015: DOD FY15 CDMRP Peer Reviewed Medical Research Program
- 2016: NIH study section ZRG1 BST-T: Bioengineering Sciences and Technologies.
- 2017: Israel Science Foundation
- 2017: NIH study section ZRG1 CVRS-N 03: LIRR Study Section.
- 2017: NIH study section NHLBI Investigator Initiated Program Project Applications (P01)
- 2017: NC3R Research program, United Kingdom
- 2017: DOD FY17 PRMRP-FP-RD
- 2018: NIH study section NHLBI Investigator Initiated Program Project Applications (P01)
- 2018: NIH-CSR-LIRR Study Section
- 2019: Deutsche Forschungsgemeinschaft
- 2019: NIH ZTR1 RD-7: Rare Diseases Study Section
- 2019: NIH ZRG1 CVRS G Lung Injury and Repair Study Section
- 2019: UKRI MRC grants
- 2019: NIH ZHL1 CSR-M, Physician Scientist- Research Award for Early Stage Investigators
- 2020: 2020/05 ZRG1 CVRS-N, Member Conflicts: Pulmonary Diseases

- 2020: DOD FY20 Peer Reviewed Medical Research Program (PRMRP)
- 2020: NIH ZRG1 CVRS-K Study Section
- 2021: NIH ZRG1 CVRS-K Study Section

Grant Support: Current

- R01 HL139897-01A1 (Wolters) Lung fibrosis mediated by telomere dysfunction in alveolar type II cells. 7/18-6/22.
- Scleroderma Research Foundation (P. Wolters PI) “Molecular Phenotyping of Scleroderma Associated Lung Disease” 7/13-6/21.
- Genentech, IPF2, Biomarker discovery and verification in IPF. 10/11-10/19.
- IIS2018- 10739 (Wolters), Boehringer Ingelheim Pharmaceuticals. Whole Exome Sequencing Study to Identify Genetic Determinants of Chronic Hypersensitivity Pneumonitis. 9/18-8/24
- R01HL142568 (Sheppard PI), Fibroblast heterogeneity in pulmonary fibrosis. 4/20-3/24
- R01HL151552 (Greenland PI) Telomere Dysfunction as a cause of Chronic Lung Allograft Dysfunction. 7/20-6/25
- SUBK00005574 (Wolters PI), Pulmonary Fibrosis Foundation Biomarker and/or Patient Registry Protocols. 11/15-10/22
- R01HL134851 (Singer PI) Frailty and patient centered outcomes in candidates for lung transplantation Time. 7/17-6/22.
- W81XWH-17-1-0597, DOD (Schwartz PI) Idiopathic Pulmonary Fibrosis, a disease initiated by mucociliary dysfunction. 9/17-8/22
- W81XWH-21-1-0417, DOD (Bhattacharya PI) Targeting ATP Receptor P2RX4 for Pulmonary Fibrosis. (8/21-7/25)
- Sanofi (Wolters PI), Lung response to injury in context of telomere dysfunction. 7/21-6/22

Grant Support: Past

- NIH P30 DK072517 (A. Verkman PI) Novel Small-Molecule Therapies for Cystic Fibrosis/Cystic Fibrosis Research and Translation Core Center. 9/05-05/19.
- NIH P01 HL108794-01 (D. Sheppard PI) “Targeting epithelial cells to treat pulmonary fibrosis”, human tissue core leader 7/12-6/17.
- NIH UM1HL119089 (H. Collard PI) Treatment of IPF with Laparoscopic Anti-reflux Surgery”, Wolters PI of ancillary study. 08/01/13-05/31/16
- Scleroderma Foundation (P. Wolters PI) “Molecular Characterization of Multiorgan Involvement in Scleroderma” 1/15-12/17.
- Bristol-Myers Squibb Company (P. Wolters PI) Cross-sectional tissue section analysis of mediators of IPF. 12/11-06/14
- NIH 1R01 HL67204, “Epithelial Mesenchymal Transition in Pulmonary Fibrosis” (H. Chapman, PI), co-investigator 1/10-12/14.
- NIH R01 HL089901-03 (R Elashoff, PI), Mycophenolate vs. Oral Cyclophosphamide in Scleroderma Interstitial Lung Disease, UCSF site co-PI 9/08-7/14.

- NIH R21 HL104422-01A1, “Identification of Type II Cell Subtypes in Fibrotic Lungs”. (P. Wolters, PI). 4/11-3/13.
- NIH RC1 ES018211-01 ARRA, “Estimating the Environmental Burden in Two Orphan Lung Diseases (P Blanc, PI) co-investigator 6/01-9/11.
- Genentech, IL-13 Biomarker discovery and verification in IPF. 10/10-1/11.
- NIH R01 HL090662-01A2 “Role of Squamous Metaplasia in Small Airways Disease in COPD” (S. Nishimura PI) co-investigator 10/09-9/11.
- NIH K08 HL04055, “Mast Cell Cysteine Proteases in Lung Inflammation” (P. Wolters, PI). 7/99-6/04
- Intermune GIPF-004, “An Open-Label Study of the Safety and Efficacy of Subcutaneous Recombinant Interferon gamma-1 β in Patients with Idiopathic Pulmonary Fibrosis” (W. Bradford, PI), P. Wolters, PI at UCSF site. 12/02-11/04
- ALA Research Grant, “Characterization of Mast Cell Cysteine Proteases” (P. Wolters, PI). 7/00-6/02
- NIH R01 HL44712, “Regulation of Integrin Functioning by the Urokinase Receptor” (H. Chapman, PI), co-investigator, 1/00-12/04
- Kosan Biosciences and Mudd Fibrosis fund, “Effects of 17-AAG on mouse lung fibrosis (G. Caughey, PI), co-investigator, 5/04-4/05.
- Intermune GIPF-007, “A Randomized, Double-Blind, Placebo-Controlled Phase III Study of the Safety and Efficacy of Subcutaneous Recombinant Interferon gamma-1 β in Patients with Idiopathic Pulmonary Fibrosis” (W. Bradford, PI), P. Wolters, PI at UCSF site. 6/04-6/07
- NIH R01 HL075026, “Mast Cells and the Host Response in Lung” (P. Wolters, PI). 7/04-6/08.

Clinical Trials/Protocols

Protocol: nd-I02-s0201-005, Nitto; *A Phase 2, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Biological Activity, and PK of ND-I02-s0201 in Subjects With Idiopathic Pulmonary Fibrosis.*

Role: Co-Investigator, UCSF, San Francisco, CA, 2017-2021.

Protocol: ISABELA2, Galapagos; *A Clinical Study to Test How Effective and Safe GLPG1690 is for Subjects With Idiopathic Pulmonary Fibrosis When Used Together With Standard of Care (ISABELA2).*

Role: Co-Investigator, UCSF, San Francisco, CA, 2019-2021.

Protocol: INBUILD, Boehringer Ingelheim; *A Double Blind, Randomized, Placebo-controlled Trial Evaluating the Efficacy and Safety of Nintedanib Over 52 Weeks in Patients With Progressive Fibrosing Interstitial Lung Disease.*

Role: Co-Investigator, UCSF, San Francisco, CA, 2017-2019.

Protocol: PRM-151, Promedior; *A Trial to Evaluate the Efficacy of PRM-151 in Subjects With Idiopathic Pulmonary Fibrosis (IPF).*

Role: Co-Investigator, UCSF, San Francisco, CA, 2016-2018.

Protocol: GBT 440, Global Blood Therapeutics; *Study to Evaluate the Safety and Tolerability of GBT440 Administered to Subjects With IPF.*

Role: Co-Investigator, UCSF, San Francisco, CA, 2016-2018.

Protocol: SENSICIS, Boehringer Ingelheim; *A Double Blind, Randomised, Placebo-controlled Trial Evaluating Efficacy and Safety of Oral Nintedanib Treatment for at Least 52 Weeks in Patients With Systemic Sclerosis Associated Interstitial Lung Disease (SSc-ILD).*

Role: Co-Investigator, UCSF, San Francisco, CA, 2015-2018.

Protocol: BMS-986020, BMS; *Safety and Efficacy of a Lysophosphatidic Acid Receptor Antagonist in Idiopathic Pulmonary Fibrosis (IPF).*

Role: Co-Investigator, UCSF, San Francisco, CA, 2013-2018.

Protocol: Lebrikizumab, Roche; *A Phase II, A Randomized, Double-Blind, Placebo-Controlled, Study to Assess the Efficacy and Safety of Lebrikizumab in Patients With Idiopathic Pulmonary Fibrosis.*

Role: Co-Investigator, UCSF, San Francisco, CA, 2013-2017.

Protocol: PIPF-016, InterMune, Inc; *A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the Efficacy and Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis.*

Role: Co-Investigator, UCSF, San Francisco, CA 2012-2013.

Protocol: PANTHER-IPF, IPF Clinical Research Network – National Institutes of Health *Prednisone, Azathioprine and N-Acetylcysteine: A Study that Evaluates Response in Idiopathic Pulmonary Fibrosis.*

Role: Co-Investigator, UCSF, San Francisco, CA, 2009-2012.

Protocol: PIPF-012, Intermune Pharmaceuticals; *An Open-Label Extension Study of the Long-Term Safety of Pirfenidone in Patients with IPF Who Complete the CAPACITY Studies*

Role: Co-Investigator, UCSF, San Francisco, CA 2011-2012.

Protocol: AC-055B201/MUSIC, Gilead; *A Double-blind, Randomized, Placebo-controlled, Multicenter, Parallel Group Study to Evaluate the Efficacy, Safety, and Tolerability of Macitentan in Patients With Idiopathic Pulmonary Fibrosis.*

Role: Co-Investigator, UCSF, San Francisco, CA, 2009-2011.

Protocol: CAPACITY, Intermune Pharmaceuticals; *Clinical Studies Assessing Pirfenidone in IPF: Research of Efficacy and Safety Outcomes*

Role: Co-Investigator, UCSF, San Francisco, CA 2007-2008.

Protocol: GIPF-007, InterMune Pharmaceuticals; *International Study of Survival Outcomes in Idiopathic Pulmonary Fibrosis (IPF) with Interferon Gamma-1 β (INSPIRE)*

Role: Co-Investigator, UCSF, San Francisco, CA, 2004-2007.

Protocol: BUILD-1, Actelion Ltd; *Bosentan Use in Interstitial Lung Disease (BUILD-1), a Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of Bosentan in Patients with Idiopathic Pulmonary Fibrosis.*

Role: Co-Investigator, UCSF, San Francisco, CA. 2004-2006.

Protocol: GIPF-001, *Intermune Pharmaceuticals; Phase III Randomized Controlled Trial of the "Safety and Efficacy of Interferon Gamma- 1 β in the Treatment of Idiopathic Pulmonary Fibrosis"*

Role: Co-Investigator, UCSF, San Francisco, CA. 2001-2002.

Genbank Entries:

AF060171 Canine dipeptidyl peptidase I cDNA

Teaching and Mentoring

Predoctoral students Supervised or Mentored

<u>Dates</u>	<u>Name</u>	<u>Program or School</u>	<u>Role</u>	<u>Current Position</u>
2001-03	Jon Mallen-St. Clair	Undergraduate researcher	Research Mentor	Asst. Professor
2002-04	S. Armando Villalta	Undergraduate researcher	Research Mentor	Asst. Professor
2003	Jacob Schulz	Medical Student	Research Mentor	Clinical Instructor
2004	Andrew McKinstry	Undergraduate researcher	Research Mentor	Asst. Professor
2007	Matthew Wheeler	BMS grad Student	Rotation Student	post-doc
2007-08	Kim Dzhagaryants	Univ. of Minnesota (Sr.)	Career Advisor	Medical Student
2007-09	Christine Chang	UC Berkeley (Sr.)	Research Mentor	Resident
2007-09	Brenda Salantes	Mills College (Sr.)	Research Mentor	Postdoc
2008	David Horn	Univ. of Minnesota (Sr.)	Career Advisor	PhD Student
2011-12	Rachel Sutherland	Medical Student	Research Mentor	Physician
2013-15	Bradley Golden	Undergraduate researcher	Research Mentor	Student
2014	Stephanie Le	Medical Student	Research mentor	Physician
2014	Preethi Padmanaban	Undergraduate researcher	Research Mentor	CLS
2015-21	Izzy Arnould	Undergraduate researcher	Research Mentor	Student
2016-18	Elizabeth Twichell	UC Berkeley (Sr.)	Research Mentor	Med Student
2016-18	Kristy Wang	Undergraduate researcher	Research Mentor	Grad Student
2017-19	Julia Mieleszko	UC Berkeley	Research Mentor	Student
2019-22	Seoyeon Lee	UC Berkeley	Research Mentor	Grad Student

Postdoctoral students Supervised or Mentored

<u>Dates</u>	<u>Name</u>	<u>Program or School</u>	<u>Role</u>	<u>Current Position</u>
2005-08	Anh Innes	Pulmonary Fellow	Career Advisor	Asst. Prof, UCSF
2005-06	Cecilia Marmai	Research Scholar	Research mentor	Asst. Prof, Florence
2007-10	Antonio Gomez	Pulmonary Fellow	Career Advisor	Asst. Prof, UCSF
2007-10	Neil Trivedi	Pulmonary Fellow	Mentoring Committee	Asst. Prof, UCSF
2008-14	Eric Seeley	Pulmonary Fellow	Research mentor	Asst. Prof, UCSF
2009-11	Seung-Ick Cha	Research Scholar	Research mentor	Assoc.Prof, Kyungpook National University
2011-12	Eun Kyung Kim	Research Scholar	Research mentor	Assoc. Professor, Cha University, Korea
2012-15	John Greenland	Pulmonary Fellow	Mentoring Committee	Asst. Professor UCSF
2012-15	Brett Ley	Pulmonary Fellow	Career/research advisor	Asst. Professor UCSF
2013	Xiaojia Wang	Postdoctoral Fellow	Research mentor	Asst. Professor
2013-15	Supparerk Disayabutr	Research Scholar	Research mentor	Assoc. Professor

2013-18	Ram Naikawadi	Postdoctoral Fellow	Research mentor	Specialist, UCSF
2014	Hui Huang	Postdoctoral Fellow	Research mentor	Professor, PUMC
2014-16	Hilary Faust	Pulmonary Fellow	Research mentor	Asst. Professor, U Wisconsin
2016-18	Shuo Liu	Research Scholar	Research mentor	Assoc. Prof, China Medical Univ.
2016-18	Meenal Sinha	Postdoctoral fellow	Research mentor	Specialist, UCSF
2016-17	Yingwei Zhang	Research Scholar	Research Mentor	Assoc. Prof, Nanjing University
2016-19	Daniel Calabrese	Pulmonary Fellow	Career/research advisor	Asst. Professor
2019-20	Jong Sun Park	Visiting Scholar	Research Mentor	Assoc Professor
2021-	Yang Monica	Rheumatology Fellow	Research Mentor	Fellow
2021-	Fred Mclafferty	Pulmonary Fellow	Research Mentor	Fellow

Recurring Resident and Fellow Teaching Responsibilities

Adult Pulmonary Medicine Attending Rounds: 280 hours/year

Daily rounds on patients enlisted to the pulmonary consult service. The rounds average 5 hours/day, seven days a week, for 8-10 weeks/year. Teaching activities involve the supervision and teaching of fellows, residents, and medical students on the pathophysiology, management respiratory problems in adult patients.

Pulmonary Medicine Conferences

Organization and participation in adult pulmonary medicine conferences

2001-present: Pulmonary Clinical Case Conference: 10 hours/year

2005-present: Pulmonary Physiology Conference: 2 hours/year

2005-present: Rheumatology Fellow Conference: 2 hours/year

2003-present: Pulmonary Critical Care Fellowship Training Program, Reviewed applications and interviewed fellows: 40 hrs/year.

Peer-Reviewed Publications

1. O'Grady SM, Wolters PJ, Hildebrand KM, and Brown DR. *Regulation of Ion Transport in Porcine Gallbladder; Effects of VIP and Norepinephrine*. Am J Physiol. 1989; 257: C52-C57.
2. O'Grady SM, and Wolters PJ. *Sodium and Chloride Transport Across the Isolated Porcine Gallbladder*. Am J Physiol. 1989; 257: C45-C51
3. O'Grady SM, and Wolters PJ. *Cardiac Antisecretory Peptide Inhibits Intestinal Chloride Secretion*. Am J Physiol. 1989; 257: C775-C780
4. Wolters PJ, Hildebrandt KM, and Anderson JS. *Polymer length of teichuronic acid released from cell walls of Micrococcus luteus*. J Bacteriol. 1990; 172: 5154-515
5. O'Grady SM, and Wolters PJ. *Evidence for Chloride Secretion in the Intestine of the Winter Flounder*. Am J Physiol. 1990; 258: C243-C247

6. Wolters PJ, Raymond WW, Blount JL, and Caughey GH. *Regulated Expression, Processing, and Secretion of Dog Mast Cell Dipeptidyl Peptidase I*. J Biol Chem. 1998; 273: 15514-15520
7. Fang KC, Wolters PJ, Steinhoff M, Bigdol A, Blount JL, and Caughey GH. *Mast Cell Expression of Gelatinases A and B is Regulated by Kit Ligand and TGF- β* J Immunol. 1999; 162: 5528-5535
8. Wolters PJ, Laig-Webster M, and Caughey GH. *Dipeptidyl Peptidase I Cleaves Matrix-Associated Proteins and is Expressed Mainly by Mast Cells in Normal Dog Airways*. Am J Respir Cell Mol Biol. 2000; 22: 183-190
9. Caughey GH, Raymond WW, and Wolters PJ. *Angiotensin II Generation by Mast Cell α - and β - Chymases*. Biochim Biophys Acta. 2000; 1480: 245-257
10. Caughey GH, Raymond WW, Blount JL, Hau LW, Pallaoro M, Wolters PJ, and Verghese GM. *Characterization of Human γ -Tryptases, Novel Members of the Chromosome 16p Mast Cell Tryptase and Proctasin Gene Families*. J Immunol. 2000; 164: 6566-6575
11. Wolters PJ, and Chapman HA. *Importance of Lysosomal Cysteine Proteases in Lung Disease*. Respiratory Research. 2000; 1: 170-177.
12. Wolters PJ, Pham CTN, Muillenbergen D, Ley, TJ, and Caughey GH. *Dipeptidyl Peptidase I is Essential for the Activation of Mast Cell Chymase, But Not Tryptase in vivo*. J Biol Chem. 2001; 276: 18551-18556.
13. Muilenburg DJ, Raymond WW, Wolters PJ, and Caughey GH. *Lys⁴⁰ but not Arg¹⁴³ Influences Selectivity of Angiotensin Conversion by Human α -Chymase*. Biochim Biophys Acta. 2002; 1596: 346-362.
14. Bhagwandin V, Hau LW, Mallen-St.Clair J, Wolters PJ, and Caughey GH. *Structure and Activity of Human Pancreasin, a Novel Tryptic Protease Expressed Primarily by the Pancreas*. J Biol Chem. 2003; 278: 3363-3371
15. Henningsson F, Wolters PJ, Chapman HA, Caughey GH, and Pejler G. *Mast Cell Cathepsins C and S Control Levels of Carboxypeptidase A and the Chymase, Mouse Mast Cell Protease 5*. Biol Chem. 2003; 384:1527-31
16. Mallen-St. Clair J, Pham CTN, Villalta SA, Caughey GH, and Wolters PJ. *Mast Cell Dipeptidyl Peptidase I Mediates Survival from Sepsis*. J Clin Invest. 2004; 113: 628-634.
17. Wolters PJ, Mallen-St. Clair J, Lewis CC, Villalta SA, Baluk P, Erle DJ, and Caughey GH. *Tissue-Selective Mast Cell Reconstitution and Differential Lung Gene Expression in Mast Cell-Deficient Kit^{W-sh}/Kit^{W-sh} Sash Mice*. Clin Exp Allergy. 2005; 35:82-8.

18. Edwards ST, Cruz AC, Donnelly S, Dazin PF, Shulman ES, Jones KD, Wolters PJ, Hoopes C, Dolganov GM, and Fang KC, *C-Kit Immunophenotyping and Metalloproteinase Expression Profiles of Mast Cells in Interstitial Lung Diseases*. J Pathol. 2005; 206: 279-90.
19. Xu X, Zhang D, Lyubynska N, Wolters PJ, Killeen NP, Baluk P, McDonald DM, Hawgood S, and Caughey GH. *Mast Cells Protect Mice From Mycoplasma Pneumonia*. Am J Resp Crit Care Med. 2006; 173: 219-225.
20. Mallen-St. Clair J, Shi GP, Sutherland RE, Chapman HA, Caughey GH, and Wolters PJ. *Cathepsins L and S are not Required for Activation of Dipeptidyl Peptidase I (Cathepsin C) in Mice*. Biological Chemistry. 2006; 387:1143-6.
21. Kim KK, Kugler MC, Wolters PJ, Robillard L, Galvez MG, Brumwell AN, Sheppard D, and Chapman HA. *Alveolar Epithelial Cell Mesenchymal Transition Develops in vivo During Pulmonary Fibrosis and is Regulated by the Extracellular Matrix*. Proc Natl Acad Sci USA. 2006; 103: 13180-13185.
22. Wang B, Huang X, Wolters PJ, Sun J, Kitamoto S, Yang M, Riese R, Leng L, Chapman HA, Finn PW, David JR, Bucala R, and Shi GP. *Cutting Edge: Deficiency of Macrophage Migration Inhibitory Factor Impairs Murine Airway Allergic Responses*. J Immunol. 2006; 177: 5779-5784.
23. Zamora AC, Marmai C, Wolters PJ, Gaxiola M, and Navarro C. *Enfermedad Pulmonar Intersticial en Esclerosis Sistematica Progresiva*. Neumologia y Cirugia de Torax. 2006; 65: S4-14.
24. Xu X, Zhang D, Wolters PJ, Killeen NP, Sullivan BM, Locksley RM, and Caughey GH. *Neutrophil Histamine Contributes to Inflammation in Mycoplasma Pneumonia*. J Exp Med. 2006; 203: 2907-2917.
25. Zamora AC, Collard HR, Wolters PJ, Webb WR, and King TE Jr. *Neurofibromatosis-Associated Lung Disease: A Case Series and Literature Review*. Eur Respir J. 2007; 29: 210-214.
26. Calfee CS, Shah SJ, Wolters PJ, Saint S, and King TE Jr. *Clinical Problem Solving. "Anchors Away"*. N Engl J Med. 2007; 365: 58-63.
27. Sun J*, Sukhova GK*, Wolters PJ*, Yang M, Kitamoto S, Libby P, MacFarlane LA, Mallen-St. Clair J, and Shi GP. *Mast Cells Promote Atherosclerosis by Releasing Pro-Inflammatory Cytokines*. (* contributed equally). Nat Med. 2007; 13: 719-724.
28. Cottrell GS, Amadesi S, Pikios S, Camerer E, Willardsen A, Murphy B, Caughey GH, Wolters PJ, Coughlin S, Pothoulakis C, Bunnett NW, and Grady EF. *Protease-Activated Receptor 2, Dipeptidyl Peptidase I and Tryptic Proteases Mediate Clostridium Difficile Toxin A-Induced Ileitis*. Gastroenterology. 2007; 32: 2422-2437.

29. Kinder BW, Collard HR, Koth LL, Daikh DI, Wolters PJ, Elicker BM, Jones K, and King TE Jr. *The clinical entity idiopathic Nonspecific Interstitial Pneumonia is an Autoimmune Disease and the Lung Manifestation of Undifferentiated Connective Tissue Disease.* Am J Resp Crit Care Med. 2007; 176: 691-697.
30. Sun J, Sukhova GK, Yang M, Wolters PJ, MacFarlane LA, Libby P, Sun C, Zhang Y, Ennis T, Thompson RW, and Shi GP. *Mast Cells Control the Pathogenesis of Abdominal Aortic Aneurysms.* J Clin Invest. 2007; 117: 3359-3368.
31. Arya J, Cambier S, Markovics JA, Wolters P, Jablons D, Hill A, Finkbeiner W, Jones K, Broaddus VC, Sheppard D, Barzac A, Erle DJ, and Nishimura S. *Squamous Metaplasia Amplifies Pathologic Epithelial-Mesenchymal Interactions in COPD Patients.* J Clin Invest. 2007; 117: 3551-3562.
32. Pottier N, Chupin C, Defamie V, Cardinaud B, Sutherland R, Rios G, Gauthier F, Wolters PJ, Berthiaume Y, Barbry P, and Mari B. *Relationships Between the Early Inflammatory Response to Bleomycin and the Sensitivity to Lung Fibrosis in Mice: a Potential Role for Dipeptidyl Peptidase I and Tissue Inhibitor of Metalloproteinase-3.* Am J Resp Crit Care Med. 2007; 176: 1098-1107.
33. Zamora AC, Wolters PJ, Collard HR, Connolly MK, Elicker BM, Webb WR, King TE Jr, and Golden JA. *The Use of Mycophenolate Mofetil to Treat Scleroderma-Associated Interstitial Lung Disease.* Respir Med. 2008; 102: 150-5.
34. Sutherland RE, Touger JS, McKinstry A, Villalta, SA, and Wolters PJ. *Mast Cell IL-6 Improves Survival Following Klebsiella Pneumonia and Sepsis by Enhancing Neutrophil Killing.* J Immunol. 2008; 181: 5598-605.
35. Kim KK, Wei Y, Szekeres C, Kugler MC, Wolters PJ, Hill ML, Frank JA, Brumwell AN, Wheeler SE, Kreidberg JA, and Chapman HA. *Epithelial Cell $\alpha 3 \beta 1$ Integrin Links β -Catenin and Smad Signaling to Promote Myofibroblast Formation and Pulmonary Fibrosis.* J Clin Invest. 2009; 119: 213-224.
36. Wolters PJ, Wray C, Sutherland RE, Kim SS, Koff J, Mao Y, and Frank JA. *Neutrophil interleukin-6 Limits Alveolar Barrier Disruption in Experimental Ventilator-Induced Lung Injury* J Immunol. 2009; 182: 8056-62.
37. Liu J, Divoux A, Sun J, Zhang J, Clément K, Glickman JN, Sukhova GK, Wolters PJ, Du J, Gorgun CZ, Doria A, Libby P, Blumberg RS, Kahn BB, Hotamisligil GS, and Shi GP. *Deficiency and Pharmacological Stabilization of Mast Cells Reduces Diet-Induced Obesity and Diabetes in Mice.* Nat Med. 2009; 15: 940-5.
38. Atabai K, Jame S, Azhar N, Kuo A, Lam M, McKleroy W, DeHart G, Rahman S, Xia DD, Melton AC, Wolters P, Emson CL, Turner SM, Werb Z, and Sheppard D. *Mfge8 Regulates Tissue Fibrosis by Binding and Targeting Collagen for Uptake by Macrophages.* J Clin Invest. 2009; 119: 3713-22.

39. Kinder BW, Shariat C, Collard HR, Koth LL, Wolters PJ, Golden JA, Panos RJ, and King TE Jr. Undifferentiated Connective Tissue Disease-Associated Interstitial Lung Disease: Changes in Lung Function. *Lung*. 2010; 188:143-9.
40. Collard HR, Calfee CS, Wolters PJ, Song JW, Brady S, Ishizaka A, Jones KD, King TE Jr., Matthay MA, Kim DS. *Plasma Biomarker Profiles in Acute Exacerbation of Pulmonary Fibrosis*. *Am J Physiol Lung Cell Mol Physiol*. 2010; 299:L3-7.
41. Markovics JA, Araya J, Cambier S, Jablons D, Hill A, Wolters PJ, and Nishimura SL. *The TGF- β Activating Integrin β 8 Subunit is Regulated by SP3 and AP-1 Transcription Factor*. *J Biol Chem*. 2010; 285:24695-70.
42. Marmai C, Sutherland RE, Kim KK, Dolganov GM, Fang X, Jiang S, Golden JA, Hoopes C, Matthay MA, Chapman HA, and Wolters PJ. *Alveolar Epithelial Cells Express Mesenchymal Proteins in Patients With Idiopathic Pulmonary Fibrosis*. *Am J Physiol Lung Cell Mol Physiol*. 2011; 301:L71-8.
43. Wootton SC, Kim DS, Kondon Y, Chen E, Lee JS, Song JW, Huh JW, Taniguchi T, Chiu C, Boushey H, Lancaster LH, Wolters PJ, DeRisi J, Ganem D, and Collard HR. *Viral Infection in Acute Exacerbation of Idiopathic Pulmonary Fibrosis*. *Am J Resp Crit Care Med*. 2011; 183: 1698-702.
44. Kitamura H, Cambier S, Somanath S, Barker T, Minagawa S, Markovics J, Goodsell A, Publicover J, De Combregghe B, Reichardt L, Jablons D, Wolters PJ, Hill A, Marks J, Lou J, Pittet JF, Gaudie J, Baron J, and Nishimura SL. *Lung Fibroblasts Regulate Dendritic Cell Trafficking, Airway Inflammation and Fibrosis, in vivo, Through Integrin α v β 8-Mediated Activation of TGF- β* . *J Clin Invest*. 2011; 121: 2863-75.
45. Seeley EJ, Sutherland RE, Kim SS, and Wolters, PJ. *Systemic Mast Cell Degranulation Increases Mortality During Polymicrobial Septic Peritonitis in Mice*. *J Leuk Biol*. 2011; 90: 591-7.
46. Markovics JA, Araya J, Cambier S, Somanath S, Gline S, Jablons D, Hill A, Wolters PJ, and Nishimura SL. *Interleukin-1 β induces increased transcriptional activation of the transforming growth factor- β activating integrin subunit β 8 through altering chromatin architecture*. *J Biol Chem*. 2011; 286: 36864-74.
47. Sutherland RE, Xu X, Kim SS, Seeley EJ, Caughey GH, and Wolters PJ. *Parasitic Infection Improves Survival Following Septic Peritonitis by Enhancing Mast Cell Responses to Bacteria in Mice*. *PLoS One*. 2011; e13876.
48. Lee JS, Ryu JH, Elicker BM, Lydell CP, Jones KD, Wolters PJ, King TE, and Collard HR. *Gastroesophageal Reflux Therapy is Associated with Longer Survival in Idiopathic Pulmonary Fibrosis*. *Am J Resp Crit Care Med*. 2011; 184: 1390-1394.

49. Jenkins G, Blanchard A, Borok Z, Bradding P, Ehrhardt C, Fisher A, Hirani N, Johnson S, Konigshoff M, Maher TM, Millar A, Parfrey H, Scotton C, Tetley T, Thickett D, and Wolters P. *In Search of the Fibrotic Epithelial Cell: Opportunities for a Collaborative Network*. Thorax. 2012; 67: 179-182
50. Lee JS, Song JW, Wolters PJ, Elicker BM, King TE Jr, Kim DS, and Collard HR. *Bronchoalveolar Lavage Pepsin Levels in Acute Exacerbation of Idiopathic Pulmonary Fibrosis*. Eur Respir J. 2012; 39: 352-8.
51. Cha SI, Chang CS, Lee JW, Matthay MA, Golden JA, Elicker BM, Jones KD, Collard HA, and Wolters PJ. *Lung Mast Cell Density Defines a Subpopulation of Patients with Idiopathic Pulmonary Fibrosis*. Histopathology. 2012; 61: 98-106.
52. Richeldi L, Ryerson CJ, Lee JS, Wolters PJ, Koth LL, Ley B, Jones KD, King TE, Ryu JH, and Collard HR. *Relative Versus Absolute Change in Forced Vital Capacity in Idiopathic Pulmonary Fibrosis*. Thorax. 2012; 67: 407-11.
53. Chen C, Kudo M, Rutaganira F, Takano H, Lee C, Atakilit A, Robinett KS, Ueda T, Wolters PJ, Shokat KM, Huang X, and Sheppard D. *Integrin $\alpha 9 \beta 1$ in Airway Smooth Muscle Suppresses Exaggerated Airway Narrowing*. J Clin Invest. 2012; 122: 2916-27.
54. Seeley EJ, Matthay MA, and Wolters PJ. *Inflection Points in Sepsis: From Local Defense to Systemic Organ Injury*. Am J Physiol Lung Cell Mol Physiol. 2012; 303: L355-63.
55. Huang F, Zhang H, Wu M, Yang H, Kudo M, Peters CJ, Woodruff PG, Solberg OD, Donne ML, Huang X, Sheppard D, Fahy JV, Wolters P, Hogan BL, Finkbeiner W, Li M, Jan YN, Jan LY, and Rock JR. *TMEM16A-CaCC modulates mucin secretion and airway smooth muscle contraction*. Proc Natl Acad Sci USA. 2012; 109: 16354-9.
56. Cha SI, Ryerson CJ, Lee JS, Barry SS, Jones KD, Elicker BM, Kim DS, Papa FR, Collard HR, and Wolters PJ. *Cleaved Cytokeratin-18 is a Mechanistically Informative Biomarker in Idiopathic Pulmonary Fibrosis*. Resp Res. 2012; 13: 105.
57. Lee JS, Kim EJ, Lynch, KL, Elicker B, Ryerson CJ, Katsumoto TR, Shum AK, Wolters PJ, Cerri S, Richeldi L, Jones KD, King TE Jr., and Collard HR. *Prevalence and Clinical Significance of Circulating Autoantibodies in Idiopathic Pulmonary Fibrosis*. Respir Med. 2013; 107: 249-55.
58. Ryerson CJ, Urbania TH, Richeldi L, Mooney J, Lee JS, Jones KD, Elicker BM, Koth LL, King TE Jr, Wolters PJ, and Collard HR. *Prevalence and Prognosis of Unclassifiable Interstitial Lung Disease*. Eur Respir J 2013; 42: 750-7.
59. Seeley EJ, Barry SS, Narala S, Matthay MA, and Wolters PJ. *Noradrenergic Neurons Regulate Monocyte Trafficking and Mortality During Gram-Negative Infection*. J Immunol. 2013; 190: 4717-24.

60. Fingerlin TE, Murphy E, Zhang W, Peljito AL, Brown KK, Steele MP, Loyd JE, Cosgrove GP, Lynch D, Groshong S, Collard HR, Wolters PJ, Bradford WZ, Kossen K, Seiwart SD, du Bios RM, Garcia CK, Devine MS, Gudmundsson G, Isaksson HJ, Kaminski N, Zhang Y, Gibson KF, Lancaster LH, Cogan JD, Mason WR, Maher TM, Molyneaux PL, Wells AU, Moffatt MF, Selman M, Pardo A, Kim DS, Crapo JD, Make BJ, Regan EA, Walek DS, Daniel JJ, Kamatani Y, Zelenika D, Smith K, McKean D, Pedersen BS, Talbert J, Kidd RN, Markin CR, Beckman KB, Lathrop M, Schwarz M, and Schwartz DA. *Genome-wide Association Study Identifies Multiple Susceptibility Loci for Pulmonary Fibrosis*. *Nature Genetics*. 2013; 45: 613-20.
61. Shum AK, Alimohammadi M, Tan CL, Cheng MH, Metzger TC, Law CS, Lwin W, Perheentupa J, Bour-Jordan H, Carel JC, Husebye ES, De Luca F, Janson C, Sargur R, Dubois N, Kajosaari M, Wolters PJ, Chapman HA, Kämpe O, and Anderson MS. *BPIFB1 is a Lung-Specific Autoantigen Associated with Interstitial Lung Disease*. *Sci Trans Med*. 2013; 5 (206) 1-10.
62. Tang CH, Seeley EJ, Huang X, Wolters PJ, and Liu L. *Increased susceptibility to Klebsiella pneumonia and mortality in GSNOR-deficient mice*. *Biochem Biophys Res Commun*. 2013; 442: 122-6.
63. Wolters PJ, Collard HR, and Jones KD. *Pathogenesis of Idiopathic Pulmonary Fibrosis*. *Annu Rev Pathol*. 2014; 9:157-79.
64. Greer AM, Wu N, Putnam AL, Woodruff PG, Wolters P, Kinet JP, Shin JS. *Serum IgE clearance is facilitated by human FcεRI internalization*. *J Clin Invest*. 2014; 124: 1187–1198.
65. Ryerson CJ, Vittinghoff E, Ley B, Lee JS, Mooney JJ, Jones KD, Elicker BM, Wolters PJ, Koth LL, King TE Jr, and Collard HR. *Predicting survival across chronic interstitial lung disease: The ILD-GAP model*. *Chest*. 2014; 145:723-8.
66. Greer AM, Matthay MA, Kukreja J, Bhakta NR, Nguyen CP, Wolters PJ, Woodruff PG, Fahy JV, Shin JS. *Accumulation of BDCA1+ dendritic cells in interstitial fibrotic lung diseases and Th2-high asthma*. *PLoS One*. 2014; 10: e99084.
67. Jaffar J, Unger S, Corte TJ, Keller M, Wolters PJ, Richeldi L, Cerri S, Prêle CM, Hansbro PM, Argraves WS, Oliver RA, Oliver BG, Black JL, and Burgess JK. *Fibulin-1 predicts disease progression in patients with idiopathic pulmonary fibrosis*. *Chest*. 2014; 146:1055-1063.
68. Chandriani S, DePianto DJ, N'Diaye EN, Abbas AR, Jackman J, Bevers J III, Ramirez-Carrozzi V, Pappu R, Kauder SE, Toy K, Ha C, Modrusan Z, Wu LC, Collard HR, Wolters PJ, Egen JG, and Arron JR. *Endogenously expressed IL13Ra2 attenuates IL13-mediated responses but does not activate signaling in human lung fibroblasts*. *J Immunol*. 2014; 193: 111-9.

69. Stuart BD, Lee JS, Kozlitina J, Noth I, Devine MS, Glazer CS, Torres F, Jones KD, Elicker BM, Kaza V, Girod CE, Ma SF, Vij R, Collard HR, Wolters PJ, and Garcia CK. *Short telomere length is associated with reduced survival in idiopathic pulmonary fibrosis*. Lancet Resp Med. 2014; 2: 557-65.
70. Minagawa S, Lou J, Seed RI, Cormier A, Wu S, Cheng Y, Murray L, Tsui P, Connor J, Herbst R, Govaerts C, Barker T, Cambier S, Yanagisawa H, Goodsell A, Hashimoto M, Brand OJ, Cheng R, Ma R, McKnelly KJ, Wen W, Hill A, Jablons D, Wolters P, Kitamura H, Araya J, Barczak AJ, Erle DJ, Reichardt L, Marks JD, Baron JL, and Nishimura SL. *Selective Targeting of TGF- β Activation to Treat Fibroinflammatory Airway Disease*. Sci Trans Med. 2014; 6; 241ra79.
71. Sutherland RE, Barry SS, Olsen JS, Salantes DB, Caughey GH, and Wolters PJ. *Dipeptidyl Peptidase I Regulates Survival from Klebsiella Pneumonia Lung infection by Processing Surfactant Protein D*. Biochem Biophys Res Commun. 2014; 450: 818-823.
72. DePianto DJ, Chandriani S, Abbas AR, Jia G, N'Diaye EN, Caplazi P, Kauder SE, Biswas S, Karnik SK, Ha C, Modrusan Z, Matthay MA, Kukreja J, Collard HR, Egen JG, Wolters PJ*, and Arron JR*. *Heterogeneous gene expression signatures correspond to distinct lung pathologies and biomarkers of disease severity in idiopathic pulmonary fibrosis*. (* co-corresponding authors) Thorax. 2015; 70:48-56.
73. Kern RM, Singer JP, Koth L, Mooney J, Golden J, Hays S, Greenland J, Wolters P, Ghio E, Jones KD, Leard L, Kukreja J, and Blanc PD. *Lung Transplantation for Hypersensitivity Pneumonitis*. Chest. 2015; 47: 1558-65.
74. Yang J, Velikoff M, Agarwal M, Disayabutr S, Wolters PJ, and Kim KK. *Overexpression of Inhibitor of DNA-Binding 2 Attenuates Pulmonary Fibrosis through Regulation of c-Abl and Twist*. Am J Path. 2015; 185: 1001-1011.
75. Kim SY, Diggans J, Pankratz D, Huang J, Pagan M, Sindy N, Tom E, Anderson J, Choi Y, Lynch DA, Steele MP, Flaherty KR, Brown KK, Farah H, Bukstein MJ, Pardo A, Selman M, Wolters PJ, Nathan SD, Colby TV, Myers JL, Katzenstein AL, Raghu G, and Kennedy GC. *Classifying usual interstitial pneumonia in patients with interstitial lung disease using machine learning on high-dimensional transcriptional data*. Lancet Resp Med. 2015; 3: 473-82.
76. Brand OJ, Somanath S, Moermans C, Yanagisawa H, Hashimoto M, Cambier S, Markovics J, Bondesson AJ, Hill A, Jablons D, Wolters P, Lou J, Marks JD, Baron JL, and Nishimura SL. *Transforming growth factor- β and Interleukin-1 β signaling pathways converge on the chemokine CCL20 promoter*. J Biol Chem. 2015; 290: 14717-14728.
77. Assayag D, Vittinghoff E, Ryerson CJ, Cocconcelli E, Tonelli R, Hu X, Elicker BM, Golden JA, Jones KD, King TE Jr, Koth LL, Lee JS, Ley B, Shum AK, Wolters PJ, Ryu JH, and Collard HR. *The effect of bronchodilators on forced vital capacity*

- measurement in patients with idiopathic pulmonary fibrosis.* Respir Med. 2015; 109: 1058-62.
78. Singer JP, Diamond JM, Gries CJ, McDonnough J, Blanc PD, Shah R, Dean MY, Hersh B, Wolters PJ, Tokman S, Arcasoy SM, Ramphal K, Greenland JR, Smith N, Heffernan P, Shah L, Shrestha P, Golden JA, Blumenthal N, Huang D, Sonett J, Hays S, Oyster M, Katz PP, Robbins H, Brown M, Leard LE, Kukreja J, Bacchetta M, Bush E, D'Ovidio F, Rushefski M, Raza K, Christie JD, and Lederer DJ. *Frailty Phenotypes, Disability, and Outcomes in Adult Candidates for Lung Transplantation.* Am J Respir Crit Care Med. 2015; 192:1325-34.
 79. Assayag D, Kim EJ, Elicker BM, Golden JA, Jones KD, King, TE Jr. Koth LL, Shum AK, Wolters PJ, Collard HR, and Lee JS. Survival in interstitial pneumonia with features of autoimmune disease: a comparison of proposed criteria. Respir Med. 2015; 109: 1326-31.
 80. Disayabutr S, Calfee CS, Collard HR and Wolters PJ. *Interstitial lung diseases in the hospitalized patient.* BMC Medicine. 2015; 13: 245.
 81. Withana NP, Ma X, McGuire HM, Verdoes M, van der Linden WA, Ofori LO, Zhang R, Li H, Sanman LE, Wei K, Yao S, Wu P, Li F, Huang H, Xu Z, Wolters PJ, Rosen GD, Collard HR, Zhu Z, Cheng Z, Bogoyo M. *Non-invasive Imaging of Idiopathic Pulmonary Fibrosis Using Cathepsin Protease Probes.* Sci Rep. 2016; 6: 19755.
 82. Greenland JR, Wong CM, Wang AS, Uchida C, Golden JA, Hays SR, Leard LE, Raja R, Singer JP, Kukreja J, Wolters PJ, Caughey GH, and Tang Q. *Donor-reactive regulatory T cell frequency increases during acute cellular rejection of lung allografts.* Transplantation. 2016; 71: 951-4.
 83. Tatler AL, Habgood A, Porte J, John AE, Stavrou A, Hodge E, Kerama-Likoko C, Violette SM, Weinreb PH, Knox AJ, Laurent G, Parfrey H, Wolters PJ, Wallace W, Alberti S, Nordheim A, and Jenkins G. *Reduced Ets domain-Containing Protein Elk1 Promotes Pulmonary Fibrosis via Increased Integrin $\alpha v \beta 6$ Expression.* J Biol Chem. 2016; 291: 9540-53.
 84. Mak AC, Tang PL, Cleveland C, Smith M, Connolly MK, Katsumoto T, Wolters PJ, Kwok PY, Criswell LA. *Whole Exome Sequencing for Identification of Potential Causal Variants for Diffuse Systemic Sclerosis.* Arth Rheum. 2016; 68: 2257-2262.
 85. Johannson KA, Elicker BM, Vittinghoff E, Assayag D, de Boer K, Golden JA, Jones KD, King TE Jr., Koth LL, Lee JS, Ley B, Wolters PJ, and Collard HR. *A Diagnostic Model For Chronic Hypersensitivity Pneumonitis.* Thorax. 2016; 71:951-954.
 86. Fingerlin TE, Zhang W, Yang IV, Ainsworth HC, Russell PH, Blumhagen RZ, Schwarz MI, Brown KK, Steele MP, Loyd JE, Cosgrove GP, Lynch DA, Groshong S, Collard HR, Wolters PJ, Bradford WZ, Kossen K, Seiwert SD, du Bois RM, Garcia CK, Devine MS, Gudmundsson G, Isaksson HJ, Kaminski N, Zhang Y, Gibson KF, Lancaster LH,

- Mahe TM, Molyneaux PL, Wells AU, Moffatt MF, Selman M, Pardo A, Kim DS, Crapo JD, Make BJ, Regan EA, Walek DS, Daniel JJ, Kamatani Y, Zelenika D, Murphy E, Smith K, McKean D, Pedersen BS, Talbert J, Powers J, Markin CR, Beckman KB, Lathrop M, Freed B, Langefeld CD, and Schwartz DA. *Genome-wide imputation study identifies novel HLA locus for pulmonary fibrosis and potential role for autoimmunity in fibrotic idiopathic interstitial pneumonia*. BMC Genet. 2016; 17: 74.
87. Disayabutr S, Kim EK, Cha SI, Green G, Naikawadi N, Jones KD, Golden JA, Schroeder A, Matthay MA, Kukreja J, Erle DJ, Collard HR, and Wolters PJ. *miR-34 miRNAs Regulate Cellular Senescence in Type II Alveolar Epithelial Cells of Patients with Idiopathic Pulmonary Fibrosis*. PLoS One. 2016; 11: e0158367.
 88. Tatler AL, Goodwin AT, Gbolahan O, Saini G, Porte J, John AE, Clifford RL, Violette SM, Weinreb PH, Parfrey H, Wolters PJ, Gauldie J, Kolb M, Jenkins G. *Amplification of TGF β induced ITGB6 gene transcription may promote pulmonary fibrosis*. PLoS One. 2016; 11: e0158047.
 89. Naikawadi RP, Disayabutr S, Mallavia B, Donne M, Green G, La JL, Rock JR, Looney MR, and Wolters PJ. *Telomere Dysfunction In Alveolar Epithelial Cells Causes Lung Remodeling and Fibrosis*. JCI Insight. 2016; 1: e86704.
 90. Lofgren S, Hinchcliff M, Carns M, Wood T, Aren K, Arroyo E, Cheung P, Kuo A, Valenzuela A, Haemel A, Wolters PJ, Gordon J, Spiera R, Assassi S, Boin F, Chung L, Fiorentino D, Utz PJ, Whitfield ML, and Khatri P. *Integrated, multicohort analysis of systemic sclerosis identifies robust transcriptional signature of disease severity*. JCI Insight. 2016; 1: e89073
 91. Morisset J, Johannson KA, Vittinghoff E, Aravena C, Elicker BM, Jones KD, Fell CD, Manganas H, Dubé BP, Wolters PJ, Collard HR, Ryerson CJ, Ley B. *Use of mycophenolate mofetil or azathioprine for the management of chronic hypersensitivity pneumonitis*. Chest. 2017; 151: 619-625.
 92. Brownell R, Moua T, Henry TS, Elicker BM, White D, Vittinghoff E, Jones KD, Urisman A, Aravena C, Johannson KA, Golden JA, King TE Jr., Wolters PJ, Collard HR, and Ley B. *Prediction of histopathologic usual interstitial pneumonia in patients with non-definitive computed tomography*. Thorax. 2017; 72: 424-429.
 93. Wang P, Jones KD, Urisman A, Elicker BM, Urbania T, Johannson KA, Assayag D, Lee J, Wolters PJ, Collard HR, and Koth LL. *Pathological Findings and Prognosis in a Large Prospective Cohort of Chronic Hypersensitivity Pneumonitis*. Chest. 2017; 152: 502-509.
 94. Jia G, Chandriani S, Abbas AR, DePianto DJ, N'Diaye EN, Yaylaoglu MB, Moore HM, Peng I, DeVoss J, Collard HR, Wolters PJ, Egen JG, and Arron JR. *CXCL14 is a candidate systemic biomarker for hedgehog signaling in idiopathic pulmonary fibrosis*. Thorax. 2017; 72: 780-787.

95. Faust HE, Golden JA, Rajalingam R, Wang AS, Green G, Hays SR, Kukreja J, Singer JP, Wolters PJ, and Greenland JR. *Short lung transplant donor telomere length is associated with decreased CLAD-free survival*. Thorax. 2017 72:1052-1054.
96. Van Dyken SJ, Liang HE, Naikawadi RP, Woodruff PG, Wolters PJ, Erle DJ, and Locksley RM. *Spontaneous Chitin Accumulation in Airways and Age-Related Fibrotic Lung Disease*. Cell. 2017; 169: 497-509.
97. Morisset J, Vittinghoff E, Lee BY, Tonelli R, Hu X, Elicker BM, Ryu JH, Jones KD, Cerri S, Manfredi A, Sebastiani M, Gross AJ, Ley B, Wolters PJ, King TE Jr, Kim DS, Collard HR, and Lee JS. *The performance of the GAP model in patients with rheumatoid arthritis associated interstitial lung disease*. Respir Med. 2017; 127: 51-56.
98. Ley B, Newton CA, Arnould I, Elicker BM, Henry TS, Vittinghoff E, Golden JA, Jones KD, Batra K, Torrealba J, Garcia CK, and Wolters PJ. *The MUC5B promoter polymorphism and telomere length in patients with chronic hypersensitivity pneumonitis*. Lancet Resp Med. 2017; 5: 639-647.
99. Morisset J, Vittinghoff E, Elicker BM, Hu X, Le S, Ryu JH, Jones KD, Haemel A, Golden JA, Boin F, Ley B, Wolters PJ, King TE Jr., Collard HR, and Lee JS. *Mortality Risk Prediction in Scleroderma-Related Interstitial Lung Disease: The SADL Model*. Chest. 2017; 152: 999-1007.
100. Wolters PJ, Blackwell TS, Eickelberg O, Loyd JE, Kaminski N, Jenkins G, Maher TM, Molina-Molina M, Noble PW, Raghu G, Richeldi L, Schwarz MI, Selman M, Wuyts WA, and Schwartz DA. *Time for a change: is idiopathic pulmonary fibrosis still idiopathic and only fibrotic?* Lancet Respir Med. 2018; 6: 154-160.
101. Morisset J, Johannson KA, Jones KD, Wolters PJ, Collard HR, Walsh SLF, Ley B, and The HP Delphi Collaborators. *Identification of Diagnostic Criteria for Chronic Hypersensitivity Pneumonitis: An International Modified Delphi Survey*. Am J Respir Crit Care Med. 2018; 197: 1036-1044.
102. Johannson KA, Vittinghoff E, Morisset J, Wolters PJ, Noth EM, Balmes JR, and Collard HR. *Air Pollution Exposure Is Associated with Lower Lung Function, but not Changes in Lung Function, in Patients with Idiopathic Pulmonary Fibrosis*. Chest. 2018; 154: 119-125.
103. Dressen A, Abbas AR, Cabanski C, Reeder J, Ramalingam TR, Neighbors M, Bhangale TR, Brauer MJ, Hunkapiller J, Reeder J, Mukhyala K, Cuenco K, Tom J, Cowgill A, Vogel J, Forrest WF, Collard HR, Wolters PJ, Kropski JA, Lancaster LH, Blackwell TS, Arron JR, and Yaspan BL. *Analysis of protein-altering variants in telomerase genes and their association with MUC5B common variant status in patients with idiopathic pulmonary fibrosis: a candidate gene sequencing study*. Lancet Respir Med. 2018; 6: 603-614.

104. Neighbors M, Cabanski CR, Ramalingam TR, Sheng XR, Tew GW, Gu C, Jia G, Peng K, Ray JM, Ley B, Wolters PJ, Collard HR, Arron JR. *Prognostic and predictive biomarkers for patients with idiopathic pulmonary fibrosis treated with pirfenidone: post-hoc assessment of the CAPACITY and ASCEND trials.* Lancet Respir Med. 2018; 6: 615-626.
105. Martin-Medina A, Lehmann M, Burgy O, Hermann S, Baarsma HA, Wagner DE, De Santis MM, Ciolek F, Hofer TP, Frankenberger M, Aichler M, Lindner M, Gesierich W, Guenther A, Walch A, Coughlan C, Wolters P, Lee JS, Behr J, and Königshoff M. *Increased Extracellular Vesicles Mediate WNT-5A Signaling in Idiopathic Pulmonary Fibrosis.* Am J Respir Crit Care Med. 2018; 198: 1527-1538.
106. Raghu G, Pellegrini CA, Yow E, Flaherty KR, Meyer K, Noth I, Scholand MB, Cello J, Ho LA, Pipavath S, Lee JS, Lin J, Maloney J, Martinez FJ, Morrow E, Patti MG, Rogers S, Wolters PJ, Yates R, Anstrom KJ, and Collard HR. *Laparoscopic anti-reflux surgery for the treatment of idiopathic pulmonary fibrosis (WRAP-IPF): a multicentre, randomised, controlled phase 2 trial.* Lancet Respir Med. 2018; 6: 707-714.
107. Juge PA, Lee JS, Ebstein E, Furukawa H, Dobrinskikh E, Gazal S, Kannengiesser C, Ottaviani S, Oka S, Tohma S, Tsuchiya N, Rojas-Serrano J, González-Pérez MI, Mejía M, Buendía-Roldán I, Falfán-Valencia R, Ambrocio-Ortiz E, Manali E, Papiris SA, Karageorgas T, Boumpas D, Antoniou K, van Moorsel CHM, van der Vis J, de Man YA, Grutters JC, Wang Y, Borie R, Wemeau-Stervinou L, Wallaert B, Flipo RM, Nunes H, Valeyre D, Saitenberg-Kermanac'h N, Boissier MC, Marchand-Adam S, Frazier A, Richette P, Allanore Y, Sibilia J, Dromer C, Richez C, Schaevebeke T, Lioté H, Thabut G, Nathan N, Amselem S, Soubrier M, Cottin V, Clément A, Deane K, Walts AD, Fingerlin T, Fischer A, Ryu JH, Matteson EL, Niewold TB, Assayag D, Gross A, Wolters P, Schwarz MI, Holers M, Solomon J, Doyle T, Rosas IO, Blauwendraat C, Nalls MA, Debray MP, Boileau C, Crestani B, Schwartz DA, Dieudé P. *MUC5B Promoter Variant and Rheumatoid Arthritis with Interstitial Lung Disease.* N. Engl J Med. 2018; 379: 2209-2219.
108. Zhang Y, Jones KD, Achta-Zadeh N, Green G, Kukreja J, Xu B, and Wolters PJ. *Histopathologic and Molecular Analysis of Idiopathic Pulmonary Fibrosis Lungs from Patients Treated with Pirfenidone or Nintedanib.* Histopathology. 2019; 74: 341-349.
109. Newton CA, Oldham JM, Ley B, Anand V, Adegunsoye A, Liu G, Batra K, Torrealba J, Kozlitina J, Glazer C, Streck ME, Wolters PJ, Noth I, and Garcia CK. *Telomere Length and Genetic Variant Associations with Interstitial Lung Disease Progression and Survival.* Eur Respir J. 2019; 53: 1801641.
110. Aran D, Looney AP, Liu L, Wu E, Fong V, Hsu A, Chak S, Naikawadi RP, Wolters PJ, Abate AR, Butte AJ, and Bhattacharya M. *Reference-based analysis of lung single-cell sequencing reveals a transitional profibrotic macrophage.* Nat Immunol. 2019; 20: 163-172.

111. Liu S, Wolters PJ, Zhang Y, Zhao M, Liu D, Wang L, Zhao G, Mao S, Wu L, Zhao H, and Wang X. *Association between greenhouse working exposure and bronchial asthma: A pilot, cross-sectional survey of 5,420 greenhouse farmers from northeast China.* J Occup Environ Hyg. 2019; 16: 286-293.
112. Tanizawa K, Ley B, Vittinghoff E, Elicker BM, Henry TS, Wolters PJ, Brownell R, Liu S, Collard HR, and Jones KD. *Significance of bronchiolocentric fibrosis in patients with histopathologic usual interstitial pneumonia.* Histopathology. 2019; 74: 1088-1097.
113. Jhajj A, Gill HP, Hague CJ, Murphy D, Elicker B, Soon J, Sulaiman N, Castillo-Saldana D, Wilcox PG, Dunne J, Lee JS, Wolters PJ, Ley B, Jones KD, Morisset J, and Ryerson CJ. *Pulmonary physiology is poorly associated with radiological extent of disease in systemic sclerosis-associated interstitial lung disease.* Eur Respir J. 2019; 53: 1802182.
114. Moore C, Blumhagen RZ, Yang IV, Walts A, Powers J, Walker T, Bishop M, Russell P, Vestal B, Cardwell J, Markin CR, Mathai SK, Schwarz MI, Steele MP, Lee J, Brown KK, Loyd JE, Crapo JD, Silverman EK, Cho MH, James JA, Guthridge JM, Cogan JD, Kropski JA, Swigris JJ, Bair C, Soon Kim D, Ji W, Kim H, Song JW, Maier LA, Pacheco KA, Hirani N, Poon AS, Li F, Jenkins RG, Braybrooke R, Saini G, Maher TM, Molyneaux PL, Saunders P, Zhang Y, Gibson KF, Kass DJ, Rojas M, Sembrat J, Wolters PJ, Collard HR, Sundry JS, O'Riordan T, Strek ME, Noth I, Ma SF, Porteous MK, Kreider ME, Patel NB, Inoue Y, Hirose M, Arai T, Akagawa S, Eickelberg O, Fernandez IE, Behr J, Mogulkoc N, Corte TJ, Glaspole I, Tomassetti S, Ravaglia C, Poletti V, Crestani B, Borie R, Kannengiesser C, Parfrey H, Fiddler C, Rassl D, Molina-Molina M, Machahua C, Montes Worboys A, Gudmundsson G, Isaksson HJ, Lederer DJ, Podolanczuk AJ, Montesi SB, Bendstrup E, Danchel V, Selman M, Pardo A, Henry MT, Keane MP, Doran P, Vašáková M, Sterclova M, Ryerson CJ, Wilcox PG, Okamoto T, Furusawa H, Miyazaki Y, Laurent G, Baltic S, Prele C, Moodley Y, Shea BS, Ohta K, Suzukawa M, Narumoto O, Nathan SD, Venuto DC, Woldehanna ML, Kokturk N, de Andrade JA, Luckhardt T, Kulkarni T, Bonella F, Donnelly SC, McElroy A, Armstrong ME, Aranda A, Carbone RG, Puppo F, Beckman KB, Nickerson DA, Fingerlin TE, and Schwartz DA. *Resequencing Study Confirms Host Defense and Cell Senescence Gene Variants Contribute to the Risk of Idiopathic Pulmonary Fibrosis.* Am J Respir Crit Care Med. 2019; 200: 199-208.
115. Liu GY, Ventura IB, Achtar-Zadeh N, Elicker BM, Jones KD, Wolters PJ, Collard HR, Adegunsoye A, Strek ME, and Ley B. *Prevalence and Clinical Significance of Antineutrophil Cytoplasmic Antibodies in North American Patients with Idiopathic Pulmonary Fibrosis.* Chest. 2019; 156: 715-723.
116. Anderson MR, Kolaitis N, Gao Y, Kukreja J, Greenland J, Hays S, Wolters P, Golden J, Diamond J, Palmer S, Arcasoy S, Udupa J, Christie JD, Lederer DJ, and Singer JP. *A non-linear relationship between visceral adipose tissue and frailty in adult lung transplant candidates.* Am J Transplant. 2019; 19: 3155–3161.

117. Ley B, Torgerson DG, Oldham JM, Adegunsoye A, Liu S, Li J, Elicker BM, Henry TS, Golden JA, Jones KD, Dressen A, Yaspan BL, Arron JR, Noth I, Hoffmann TJ, and Wolters PJ. *Rare Protein-altering Telomere-related Gene Variants in Patients with Chronic Hypersensitivity Pneumonitis*. Am J Respir Crit Care Med. 2019; 200: 1154-1163.
118. Liu S, Wang C, Green G, Zhuo H, Liu KD, Kangelaris KN, Gomez A, Jauregui A, Vessel K, Ke S, Hendrickson C, Matthay MA, Calfee CS, Ware LB, and Wolters PJ. *Peripheral Blood Leukocyte Telomere Length is Associated with Survival of Sepsis Patients*. Eur Respir J. 2020; 55: 1901044.
119. Chapman HA, Wei Y, Montas G, Leong D, Golden JA, Trinh BN, Wolters PJ, Le Saux CJ, Jones KD, Hills NK, Foster E, Oldham JM, Linderholm AL, Kotak P, Decaris M, Turner S, and Song JW. *Reversal of TGF β 1-Driven Profibrotic State in Patients with Pulmonary Fibrosis*. N Engl J Med. 2020; 382: 1068-1070.
120. Tsukui T, Sun KH, Wetter JB, Wilson-Kanamori JR, Hazelwood LA, Henderson NC, Adams TS, Schupp JC, Poli SD, Rosas IO, Kaminski N, Matthay MA, Wolters PJ, and Sheppard D. *Collagen-producing lung cell atlas identifies multiple subsets with distinct localization and relevance to fibrosis*. Nat Commun. 2020; 11: 1920.
121. Zhang K, Yao E, Lin C, Chou YT, Wong J, Li J, Wolters PJ, and Chuang PT. A mammalian *Wnt5a-Ror2-Vangl2* axis controls the cytoskeleton and confers cellular properties required for alveologenesis. Elife. 2020; 9: e53688.
122. Podolsky MJ, Yang CD, Lizama C, Datta R, Huang SK, Nishimura SL, Dallas SL, Wolters P, Jourdan Le Saux C, and Atabai K. *Age-dependent regulation of cell-mediated collagen turnover*. JCI Insight. 2020; 5: e137519.
123. Ley B, Liu S, Elicker BM, Henry TS, Vittinghoff E, Golden JA, Jones KD, and Wolters PJ. *Telomere length in patients with unclassifiable interstitial lung disease: a cohort study*. Eur Respir J. 2020; 56: 2000268
124. Venado A, Kolaitis NA, Huang CY, Gao Y, Glidden DV, Soong A, Sutter N, Katz PP, Greenland JR, Calabrese DR, Hays SR, Golden JA, Shah RJ, Leard LE, Kukreja J, Deuse T, Wolters PJ, Covinsky K, Blanc PD, and Singer JP. *Frailty after lung transplantation is associated with impaired health-related quality of life and mortality*. Thorax. 2020; 75: 669-678.
125. Wang C, Wolters PJ, Calfee CS, Liu S, Balmes JR, Zhao Z, Koyama T, and Ware LB. *Long-term ozone exposure is positively associated with telomere length in critically ill patients*. Environ Int. 2020; 141:105780.
126. Naikawadi RP, Green G, Jones KD, Achta-Zadeh N, Mielezsko JE, Arnould I, Kukreja J, Greenland J, and Wolters PJ. *Airway Epithelial Telomere Dysfunction Drives Remodeling Similar to Chronic Lung Allograft Dysfunction*. Am J Respir Cell Mol Biol. 2020; 63: 490-501.

127. Furusawa H, Cardwell JH, Okamoto T, Walts AD, Konigsberg IR, Kurche JS, Bang TJ, Schwarz MI, Brown KK, Kropski JA, Rojas M, Cool CD, Lee JS, Wolters PJ, Yang IV, and Schwartz DA. *Chronic Hypersensitivity Pneumonitis, an Interstitial Lung Disease With Distinct Molecular Signatures*. Am J Respir Crit Care Med. 2020; 202:1430-1444.
128. Wang BR, Edwards R, Freiheit EA, Ma Y, Burg C, de Andrade J, Lancaster L, Lindell K, Nathan SD, Raghu G, Gibson K, Gulati M, Mason W, Noth I, Schmidt B, Spino C, Staszak S, Stauffer J, Wolters PJ, Cosgrove GP, and Flaherty KR. *The Pulmonary Fibrosis Foundation Patient Registry: Rationale, Design, and Methods*. Ann Am Thorac Soc. 2020; 17: 1620-1628.
129. Baluk P, Naikawadi RP, Kim S, Rodriguez F, Choi D, Hong YK, Wolters PJ, and McDonald DM. *Lymphatic proliferation ameliorates pulmonary fibrosis after lung injury*. Am J Pathol. 2020; 190: 2355-2375.
130. Cassandras M, Wang C, Kathiriya J, Tsukui T, Matatia P, Matthay M, Wolters P, Molofsky A, Sheppard D, Chapman H, and Peng T. *Gli1 + mesenchymal stromal cells form a pathological niche to promote airway progenitor metaplasia in the fibrotic lung*. Nat Cell Biol. 2020; 22:1295-1306.
131. Gao X, Jia G, Guttman A, DePianto DJ, Morshead KB, Sun KH, Ramamoorthi N, Vander Heiden JA, Modrusan Z, Wolters PJ, Jahreis A, Arron JR, Khanna D, Ramalingam TR. *Osteopontin Links Myeloid Activation and Disease Progression in Systemic Sclerosis*. Cell Rep Med. 2020; 1: 100140.
132. Adegunsoye A, Morisset J, Newton CA, Oldham JM, Vittinghoff E, Linderholm AL, Strek ME, Noth I, Garcia CK, Wolters PJ, and Ley B. *Leukocyte Telomere Length and Mycophenolate Therapy in Chronic Hypersensitivity Pneumonitis*. Eur Respir J. 2021 57: 2002872.
133. N'Diaye EN, Cook R, Wang H, Wu P, LaCanna R, Wu C, Ye Z, Seshasayee D, Hazen M, Lin W, Tyagi T, Hotzel I, Tam L, Newman R, Roose-Girma M, Wolters PJ, and Ding N. *Extracellular BMP1 is the major proteinase for C-terminal proteolysis of type I procollagen in lung fibroblasts*. Am J Physiol Cell Physiol. 2021; 320: C162-C174.
134. Lee JS, La J, Aziz S, Dobrinskikh E, Brownell R, Jones KD, Achta-Zadeh N, Green G, Elicker BM, Golden JA, Matthay MA, Kukreja J, Schwartz DA, and Wolters PJ. *Molecular Markers of Telomere Dysfunction and Senescence are Common Findings in the Usual Interstitial Pneumonia Pattern of Lung Fibrosis*. Histopathology. 2021; 79: 67-76.
135. Wei Y, Dong W, Jackson J, Ho TC, Le Saux CJ, Brumwell A, Li X, Klesney-Tait J, Cohen ML, Wolters PJ, and Chapman HA. *Blocking LOXL2 and TGFβ1 signalling induces collagen I turnover in precision-cut lung slices derived from patients with idiopathic pulmonary fibrosis*. Thorax. 2021; 76: 729-732.

136. Adler BL, Boin F, Wolters PJ, Bingham CO, Shah AA, Greider C, Casciola-Rosen L, and Rosen A. *Autoantibodies targeting telomere-associated proteins in systemic sclerosis*. Ann Rheum Dis. 2021; 80: 912-919.
137. Maheshwari JA, Kolaitis NA, Anderson MR, Benvenuto L, Gao Y, Katz PP, Greenland J, Wolters PJ, Covinsky K, Hays SR, Kukreja J, Calabrese DR, Venado A, Shah RJ, Leard LE, Trinh B, Huang CY, Glidden D, Kleinhenz ME, Golden JA, Sutter N, Tietje-Ulrich G, Criner RN, Arcasoy SM, Christie JD, Diamond J, and Singer JP. *Construct and Predictive Validity of Sarcopenia in Lung Transplant Candidates*. Ann Am Thorac Soc. 2021; 18: 1464-1474.
138. DePianto DJ, Vander Heiden JA, Morshead KB, Sun KH, Modrusan Z, Teng G, Wolters PJ, and Arron JR. *Molecular mapping of interstitial lung disease reveals a phenotypically distinct senescent basal epithelial cell population*. JCI Insight. 2021; 6: e143626.
139. Nakanishi T, Cerani A, Forgetta V, Zhou S, Allen RJ, Leavy OC, Koido M, Assayag D, Jenkins RG, Wain LV, Yang IV, Lathrop GM, Wolters PJ, Schwartz DA, and Richards JB. *Genetically increased circulating FUT3 level leads to reduced risk of Idiopathic Pulmonary Fibrosis: a Mendelian Randomisation Study*. Eur Respir J. 2022; 59: 2003979. doi: 10.1183/13993003.03979-2020.
140. Liu S, Chung MP, Ley B, French S, Elicker BM, Fiorentino DF, Chung LS, Boin F, and Wolters PJ. *Peripheral blood leucocyte telomere length is associated with progression of interstitial lung disease in systemic sclerosis*. Thorax. 2021 76:1186-1192.
141. Sun T, Huang Z, Liang WC, Yin J, Lin WY, Wu J, Vernes JM, Lutman J, Caplazi P, Jeet S, Wong T, Wong M, DePianto DJ, Morshead KB, Sun KH, Modrusan Z, Vander Heiden JA, Abbas AR, Zhang H, Xu M, N'Diaye EN, Roose-Girma M, Wolters PJ, Yadav R, Sukumaran S, Ghilardi N, Corpuz R, Emson C, Meng YG, Ramalingam TR, Lupardus P, Brightbill HD, Seshasayee D, Wu Y, and Arron JR. *TGF β 2 and TGF β 3 isoforms drive fibrotic disease pathogenesis*. Sci Transl Med. 2021;13: eabe0407.
142. Juge PA, Solomon JJ, van Moorsel CHM, Garofoli R, Lee JS, Louis-Sydney F, Rojas-Serrano J, González-Pérez MI, Mejia M, Buendia-Roldán I, Falfán-Valencia R, Ambrocio-Ortiz E, Manali E, Papiris SA, Karageorgas T, Boumpas D, Antoniou KM, Sidiropoulos P, Trachalaki A, van der Vis JJ, Jamnitski A, Grutters JC, Kannengiesser C, Borie R, Kawano-Dourado L, Wemeau-Stervinou L, Flipo RM, Nunes H, Uzunhan Y, Valeyre D, Saidenberg-Kermanac'h N, Boissier MC, Richez C, Schaevebeke T, Doyle T, Wolters PJ, Debray MP, Boileau C, Porcher R, Schwartz DA, Crestani B, and Dieudé P. *MUC5B promoter variant rs35705950 and rheumatoid arthritis associated interstitial lung disease survival and progression*. Semin Arthritis Rheum. 2021;51: 996-1004.
143. Arora S, Thompson PJ, Wang Y, Bhattacharyya A, Apostolopoulou H, Hatano R, Naikawadi RP, Shah A, Wolters PJ, Koliwad S, Bhattacharya M, and Bhushan A.

- Invariant Natural Killer T cells coordinate removal of senescent cells.* Med (N Y). 2021; 2: 938-950.
144. Johansson KA, Chaudhuri N, Adegunsoye A, and Wolters PJ. *Treatment of fibrotic interstitial lung disease: current approaches and future directions.* Lancet. 2021; 398: 1450-1460.
 145. Matson SM, Lee SJ, Peterson RA, Achta-Zadeh NA, Boin F, Wolters PJ, and Lee JS. *The prognostic role of matrix metalloproteinase-7 (MMP-7) in scleroderma associated interstitial lung disease.* Eur Respir J. 2021; 58: 2101560.
 146. Decaris ML, Schaub JR, Chen C, Cha J, Lee GG, Rexhepaj M, Ho SS, Rao V, Marlow MM, Kotak P, Budi EH, Hooi L, Wu J, Fridlib M, Martin SP, Huang S, Chen M, Muñoz M, Hom TF, Wolters PJ, Desai TJ, Rock F, Leftheris K, Morgans DJ, Lepist EI, Andre P, Lefebvre EA, and Turner SM. *Dual inhibition of $\alpha_v\beta_6$ and $\alpha_v\beta_1$ reduces fibrogenesis in lung tissue explants from patients with IPF.* Respir Res. 2021 19; 22: 265.
 147. Lee S, Islam MN, Boostanpour K, Aran D, Jin G, Christenson S, Matthay MA, Eckalbar WL, DePianto DJ, Arron JR, Magee L, Bhattacharya S, Matsumoto R, Kubota M, Farber DL, *Bhattacharya J, *Wolters PJ, and *Bhattacharya M. *Molecular programs of fibrotic change in aging human lung.* Nat Commun. 2021; 12: 6309. (*Contributed equally)
 148. Wang P, Leung J, Lam A, Lee S, Calabrese DR, Hays SR, Golden JA, Kukreja J, Singer JP, Wolters PJ, Tang Q, Greenland JR. *Lung transplant recipients with idiopathic pulmonary fibrosis have impaired alloreactive immune responses.* J Heart Lung Transplant. 2022; 41:641-653.
 149. Kathiriya JJ, Wang C, Zhou M, Brumwell A, Cassandras M, Le Saux CJ, Cohen M, Alysandratos KD, Wang B, Wolters P, Matthay M, Kotton DN, Chapman HA, and Peng T. *Human alveolar type 2 epithelium transdifferentiates into metaplastic KRT5 + basal cells.* Nat Cell Biol. 2022; 24: 10-23.
 150. Furusawa H, Peljto AL, Walts AD, Cardwell J, Molyneaux PL, Lee JS, Fernández Pérez ER, Wolters PJ, Yang IV, and Schwartz DA. *Common idiopathic pulmonary fibrosis risk variants are associated with hypersensitivity pneumonitis.* Thorax 2022; 77:508-510.
 151. Headland SE, Dengler HS, Xu D, Teng G, Everett C, Ratsimandresy RA, Yan D, Kang J, Ganeshan K, Nazarova EV, Gierke S, Wedeles CJ, Guidi R, DePianto DJ, Morshead KB, Huynh A, Mills J, Flanagan S, Hambro S, Nunez V, Klementowicz JE, Shi Y, Wang J, Bevers J 3rd, Ramirez-Carrozzi V, Pappu R, Abbas A, Vander Heiden J, Choy DF, Yadav R, Modrusan Z, Panettieri RA Jr, Koziol-White C, Jester WF Jr, Jenkins BJ, Cao Y, Clarke C, Austin C, Lafkas D, Xu M, Wolters PJ, Arron JR, West NR, and Wilson MS. *Oncostatin M expression induced by bacterial triggers drives airway inflammatory and mucus secretion in severe asthma.* Sci Transl Med. 2022; 14: eabf8188.

152. Boecking CA, Walentek P, Zlock LT, Sun DI, Wolters PJ, Ishikawa H, Jin BJ, Haggie PM, Marshall WF, Verkman AS, and Finkbeiner WE. *A simple method to generate human airway epithelial organoids with externally-oriented apical membranes*. Am J Physiol Lung Cell Mol Physiol. 2022; 322: L420-L437.
153. Bowman WS, Newton CA, Linderholm AL, Neely ML, Pugashetti JV, Kaul B, Vo V, Echt GA, Leon W, Shah RJ, Huang Y, Garcia CK, Wolters PJ, and Oldham JM. *Proteomic biomarkers of progressive fibrosing interstitial lung disease: a multicentre cohort analysis*. Lancet Respir Med. 2022; 10: 593-602.
154. Zhang K, Yao E, Chen B, Chuang E, Wong J, Seed RI, Nishimura SL, Wolters PJ, and Chuang PT. *Acquisition of cellular properties during alveolar formation requires differential activity and distribution of mitochondria*. Elife. 2022; 11: e68598.
155. Wilson C, Mertens TC, Shivshankar P, Bi W, Collum SD, Wareing N, Ko J, Weng T, Naikawadi RP, Wolters PJ, Maire P, Jyothula SS, Thandavarayan RA, Ren D, Elrod ND, Wagner EJ, Huang HJ, Dickey BF, Ford HL, and Karmouty-Quintana H. *Sine oculis homeobox homolog 1 (Six1) plays a critical role in pulmonary fibrosis*. JCI Insight. 2022; 7: e142984.
156. Zhang K, Yao E, Wang SA, Chuang E, Wong J, Minichiello L, Schroeder A, Eckalbar W, Wolters PJ, and Chuang PT. *A functional circuit formed by the autonomic nerves and myofibroblasts controls mammalian alveolar formation for gas exchange*. Dev Cell. 2022 (in press)
157. Borie R, Cardwell J, Konigsberg IR, Moore CM, Zhang W, Sasse SK, Gally F, Dobrinskikh E, Walts A, Powers J, Brancato J, Rojas M, Wolters PJ, Brown KK, Blackwell TS, Nakanishi T, Richards JB, Gerber AN, Fingerlin TE, Sachs N, Pulit SL, Zappala Z, Schwartz DA, Yang IV. *Colocalization of Gene Expression and DNA Methylation with Genetic Risk Variants Supports Functional Roles of MUC5B and DSP in Idiopathic Pulmonary Fibrosis*. Am J Respir Crit Care Med. 2022 (in press)
158. Xi Y, LaCanna R, Ma HY, N'Diaye EN, Gierke S, Caplazi P, Sagolla M, Huang Z, Lucio L, Arlantino A, Jeet S, Brightbill H, Emson C, Wong A, Morshead KB, DePianto DJ, Roose-Girma M, Yu C, Tam L, Jia G, Ramalingam TR, Marsters S, Ashkenazi A, Kim SH, Kelly R, Wu S, Wolters PJ, Feldstein AE, Vander Heiden JA, and Ding N. *A WISP1 antibody inhibits MRTF signaling to prevent the progression of established liver fibrosis*. Cell Metab. 2022 (in press)

Non-Authored Publications (Contributions noted in acknowledgments)

1. Tashkin DP, Elashoff R, Clements PJ, Roth MD, Furst DE, Silver RM, Goldin J, Arriola E, Strange C, Bolster MB, Seibold JR, Riley DJ, Hsu VM, Varga J, Schraufnagel D, Theodore A, Simms R, Wise R, Wigley F, White B, Steen V, Read C, Mayes M, Parsley E, Mubarak K, Connolly MK, Golden J, Olman M, Fessler B, Rothfield N, Metersky M; *Scleroderma Lung Study Research Group*. *Cyclophosphamide versus placebo in scleroderma lung disease*. N Engl J Med. 2006; 354: 2655-2666.

2. Tashkin DP, Elashoff R, Clements PJ, Roth MD, Furst DE, Silver RM, Goldin J, Arriola E, Strange C, Bolster MB, Seibold JR, Riley DJ, Hsu VM, Varga J, Schraufnagel D, Theodore A, Simms R, Wise R, Wigley F, White B, Steen V, Read C, Mayes M, Parsley E, Mubarak K, Connolly MK, Golden J, Olman M, Fessler B, Rothfield N, Metersky M, Khanna D, Li N, Li G; Scleroderma Lung Study Research Group. *Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease*. Am J Respir Crit Care Med. 2007; 176: 1026-1034
3. Strange C, Bolster MB, Roth MD, Silver RM, Theodore A, Goldin J, Clements P, J Chung J, Elashoff RM, Suh R, Smith EA, Furst DE, Tashkin DP; *Scleroderma Lung Study Research Group* *Bronchoalveolar lavage and response to cyclophosphamide in scleroderma interstitial lung disease*. Am J Respir Crit Care Med. 2008; 177: 91-98.
4. Goldin JG, Lynch DA, Stollo DC, Suh RD, Schraufnagel DE, Clements PJ, Elashoff RM, Furst DE, Vasunilashorn S, McNitt-Gray MF, Brown MS, Roth MD, Tashkin DP; Scleroderma Lung Study Research Group. *High-resolution CT scan findings in patients with symptomatic scleroderma-related interstitial lung disease*. Chest. 2008; 134: 358-367.
5. King TE, Jr., Albera C, Bradford WZ, Costabel U, Hormel P, Lancaster L, Noble PW, Sahn SA, Szwarcberg J, Thomeer M, Valeyre D, and Du Bois RM. *Effect of interferon gamma-1 β on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial*. Lancet. 2009; 374: 210-221.
6. The Idiopathic Pulmonary Fibrosis Clinical Research Network. *A Controlled Trial of Sildenafil in Advanced Idiopathic Pulmonary Fibrosis*. N Engl J Med. 2010; 363: 620-628.
7. Bois RM, Weycker D, Albera C, Bradford WZ, Costabel U, Kartashov A, Lancaster L, Noble PW, Sahn SA, Szwarcberg J, Thomeer M, Valeyre D, King TE Jr. *Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference*. Am J Respir Crit Care Med. 2011 183: 1231-1237.
8. The Idiopathic Pulmonary Fibrosis Clinical Research Network. *Prednisone, Azathioprine, and N-Acetylcysteine for Pulmonary Fibrosis*. N Engl J Med. 2012; 366:1968-1977.
9. Collard HR, Yow E, Richeldi L, Anstrom KJ, Glazer C; IPFnet investigators. *Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials*. Respir Res. 2013; 14: 73.
10. The Idiopathic Pulmonary Fibrosis Clinical Research Network. *Randomized Trial of Acetylcysteine in Idiopathic Pulmonary Fibrosis*. N Engl J Med. 2014; 370: 2093-2101.

11. Swigris JJ, Streiner DL, Brown KK, Belkin A, Green KE, Wamboldt FS; IPFnet Investigators. *Assessing exertional dyspnea in patients with idiopathic pulmonary fibrosis*. *Respir Med*. 2014; 108: 181-8.
12. de Andrade J, Schwarz M, Collard HR, Gentry-Bumpass T, Colby T, Lynch D, Kaner RJ; IPFnet Investigators. *The Idiopathic Pulmonary Fibrosis Clinical Research Network (IPFnet): Diagnostic and Adjudication Processes*. *Chest*. 2015; 148: 1034-42.
13. Tashkin DP, Tseng CH, Kim HJ, Goldin J, Clements P, Furst D, Khanna D, Kleerup E, Roth MD, and Elashoff R. *Relationship between quantitative radiographic assessments of interstitial lung disease and physiological and clinical features of systemic sclerosis*. *Ann Rheum Dis*. 2016; 75: 374-381.
14. Namas R, Tashkin DP, Furst DE, Wilhalme H, Tseng CH, Roth MD, Kafaja S, Volkmann E, Clements PJ, Khanna D; Participants in the Scleroderma Lung Study I and members of the Scleroderma Lung Study II Research Group. *Efficacy of Mycophenolate Mofetil and Oral Cyclophosphamide on Skin Thickness: Post Hoc Analyses From Two Randomized Placebo-Controlled Trials*. *Arthritis Care Res (Hoboken)*. 2018; 70: 439-444.
15. Volkmann ER, Tashkin DP, Sim M, Li N, Goldmuntz E, Keyes-Elstein L, Pinckney A, Furst DE, Clements PJ, Khanna D, Steen V, Schraufnagel DE, Arami S, Hsu V, Roth MD, Elashoff RM, Sullivan KM; SLS I and SLS II study groups. *Short-term progression of interstitial lung disease in systemic sclerosis predicts long-term survival in two independent clinical trial cohorts*. *Ann Rheum Dis*. 2019; 78(1):122
16. Lim RK, Humphreys CJ, Morisset J, Holland AE, and Johansson KA. *Oxygen in Patients with Fibrotic Interstitial Lung Disease: An International Delphi Survey*. *Eur Respir J*. 2019; 54: 1900421 [<https://doi.org/10.1183/13993003.00421-2019>].
17. Roman J, Barnes TR, Kervitsky DJ, Cosgrove GP, Doherty DE, Tager AM, Richeldi L, White ES, Brenner DA, Schnapp LM, Hewitson TD, Jugdutt BI, McKinsey TA, Tosi JD, Crane S, Brown KK; Fibrosis Across Organs Symposium Working Group. *The Fibrosis Across Organs Symposium: A Roadmap for Future Research Priorities*. *Am J Med Sci*. 2019; 357:405-410.
18. Barnes H, Morisset J, Molyneaux P, Westall G, Glaspole I, and Collard HR; CHP Exposure Assessment Collaborators. *A Systematically Derived Exposure Assessment Instrument for Chronic Hypersensitivity Pneumonitis*. *Chest*. 2020; 57: 1506-1512.
19. Graney BA, He C, Marll M, Matson S, Bianchi P, Cosgrove GP, and Lee JS; PFF CCN Delphi Collaborators. *Essential Components of an Interstitial Lung Disease Clinic: Results from a Delphi Survey and Patient Focus Group Analysis*. *Chest*. 2020 159:1517-1530.

20. Lee J, White E, Freiheit E, Scholand MB, Streck ME, Podolanczuk AJ, Patel NM; Pulmonary Fibrosis Foundation. *Cough-Specific Quality of Life Predicts Disease Progression Among Patients With Interstitial Lung Disease: Data From the Pulmonary Fibrosis Foundation Patient Registry*. Chest. 2022 (in press)

Abstracts and Poster Presentations

1. Wolters PJ, Raymond WW, Blount JL, and Caughey GH. *Purification and characterization of mast cell dipeptidyl peptidase I*. FASEB. 1997; 11: A1398
2. Wolters PJ, Raymond WW, and Caughey GH. *Mast Cells Secrete Dipeptidyl Peptidase I, Which Cleaves Fibronectin*. FASEB. 1998; 12: A5196
3. Raymond WW, Hartmann T, Koerber KK, Wolters PJ, Kitamura M, Ruoss SJ, and Caughey GH. *Expression, Activation, and Characterization of Recombinant Human Mast Cell pro- α -Chymase*. FASEB. 1998; 12: A519
4. Wolters PJ, Webster M. and Caughey GH. *Mast Cells are the Principle Source of Dipeptidyl Peptidase I in Normal Dog Airways*. Am J Respir Crit Care Med. 1999; 159: A190
5. Wolters PJ, Muilenburg DJ, Pham CT, Ley TJ, and Caughey GH. *Dipeptidyl Peptidase I Regulates Mast Cell Serine Protease Activity in Mice*. Am J Respir Crit Care Med. 2001; 163: A595
6. Wolters PJ, Mallen-St. Clair J, Pham CTN, Ley TJ, and Caughey GH. *Dipeptidyl Peptidase I Increases Mouse Mortality From Sepsis* A55, American Thoracic Society Meeting, May 2002
7. Mallen-St. Clair J, Pham CTN, Villalta SA, Caughey GH, and Wolters PJ. *Dipeptidyl Peptidase I Modulates Sepsis Survival By Influencing Levels of IL-6*. Keystone symposia: Molecular and Cellular Basis of Septic Shock. March 2003
8. Mallen-St. Clair J, Pham CTN, Villalta SA, Caughey GH, and Wolters PJ. *Mast Cell Dipeptidyl Peptidase I Modulates Sepsis Survival by Regulating Levels of IL-6*. Keystone symposia: Mast Cells in Host Defense, Physiology and Disease. March 2004
9. Wolters PJ, Rand R, Robillard L, Jablons DM, Dolganov GM, Fang X, Matthay MA, and Chapman HA. *Expression of Mesenchymal Genes in Alveolar Epithelial Cells from Patients with Idiopathic Pulmonary Fibrosis*. 13th International Colloquium on Lung Fibrosis. October 2004
10. Wolters, PJ, Touger J, McKinstry AM. *Mast Cell IL-6 Prevents Death From Septic Peritonitis*". Mast cell signaling and function in health and disease. Eilat, Israel, February 2005

11. Wolters PJ, Rand R, Robillard L, Jablons DM, Dolganov GM, Fang X, Matthay MA, and Chapman HA. *Expression of Mesenchymal Genes in Alveolar Epithelial Cells from Patients with Idiopathic Pulmonary Fibrosis*. ATS meeting San Diego, CA, May 2005
12. Xu X, Zhang DJ, Wolters PJ, Killeen NP, Caughey GH. *Cells other than mast cells and Basophils are Major Sources of Histamine in Mycoplasma Bronchitis and Pneumonia*. Am J Resp Crit Care Med. 2006; 173: A285.
13. Zamora, AC, Wolters PJ, Collard HR, Connelly MK, Elicker BM, Webb WR, Tchao N, Koth LL, King TE, Jr., Golden JA. *Mycophenolate Mofetil in Scleroderma-Related Interstitial Lung Disease*. Am J Resp Crit Care Med. 2006; 173: A723.
14. Wray C, Wolters PJ, Erle D, Matthay MA, Frank JA. *Interleukin-6 Does Not Affect Alveolar Epithelial Barrier Dysfunction in Experimental Ventilator-Induced Lung Injury*. Am J Resp Crit Care Med. 2006; 173:A246.
15. Sutherland RE, Touger JS, Ly GM, McKinstry A, and Wolters PJ. *IL-6 Improves Survival Following Klebsiella Pneumonia by Enhancing Neutrophil Killing of Bacteria*. Am J Resp Crit Care Med. 2006; 173: A837.
16. Marmai C, Sutherland RE, Robillard L, Hoopes C, Theodore P, Chapman HA and Wolters PJ. *Alveolar Epithelial Cell Subtypes in Idiopathic Pulmonary Fibrosis*. 14th International Colloquium on Lung Fibrosis. September 2006
17. Wolters PJ, Sutherland RE, Touger JS, and McKinstry A. *Mast Cell IL-6 Improves Survival Following Klebsiella Pneumonia and Sepsis by Enhancing Neutrophil Killing*. Keystone symposia: Mast Cells, Basophils, and IgE: Host Defense and Disease. January 2007
18. Araya, J, Cambier SD, Jablons D, Wolters PJ, Hill A, Barbeau R, Barczak A, Xiao Y, Erle DJ, Broaddus VC, Finkbeiner W, Nishimura SL. *The Role of Squamous Metaplasia in Airway Remodeling*. Am J Resp Crit Care Med. 2007; 175: A35.
19. Wray C, Wolters PJ, Sutherland R, Matthay MA, McAuley D, Frank JA. *Neutrophil-Derived Interleukin-6 and Alveolar Barrier Dysfunction in Experimental Ventilator-Induced Lung Injury*, Am J Resp Crit Care Med. 2007; 175: A785.
20. Marmai C, Sutherland RE, Chapman HA, Wolters PJ. *Alveolar Epithelial Cell Subtypes in Idiopathic Pulmonary Fibrosis and Normal Lung*. Am J Resp Crit Care Med. 2007; 175: A985
21. Kinder BW, Collard HR, Koth L, Daikh DI, Wolters PJ, King TE, Jr. *Nonspecific Interstitial Pneumonia Is the Pulmonary Manifestation of Undifferentiated Connective Tissue Disease*. Am J Resp Crit Care Med. 2007; 175: A365.

22. Cottrell GS, Amadesi S, Pikios S, Camerer E, Willardsen A, Murphy B, Caughey G, Wolters P, Coughlin SR, Peterson A, Knecht W, Pothoulakis C, Burnett NW, Grady EE. *Protease-activated receptor 2, dipeptidyl peptidase I and tryptic proteases mediate Clostridium difficile toxin a-induced ileitis in mice.* Gastroenterology. 2007; 132: A388.
23. Xu X, Zhang H, Wolters PJ, Lowell CA, and Caughey GH. *Mast Cell Histamine Limits Neutrophilic Inflammation.* Am J Resp Crit Care Med. 2008 175: A39.
24. Kinder BW, Shariat C, Collard HR, Koth LL, Wolters PJ, Golden JA, Panos RJ, and King TE Jr. *Clinical Course of Undifferentiated Connective Tissue Disease-ILD Is More Favorable Than Idiopathic Pulmonary Fibrosis.* Am J Resp Crit Care Med. 2008 175: A248.
25. Wolters PJ, Sutherland RE, Touger JS, and McKinstry A. *Dipeptidyl Peptidase I Modulates Survival Following Klebsiella Pneumonia by Regulating Levels of Surfactant Protein D.* Am J Resp Crit Care Med. 2008 175: A35.
26. Marmai C, Kim KK, Sutherland RE, Matthay MA, Chapman HA, and Wolters PJ. *Human Alveolar Type II Cells Acquire Features of Mesenchymal Cells When Cultured on Fibronectin.* 15th International Colloquium on Lung Fibrosis. September 2008.
27. Kinder BW, McCormack FX, Collard HR, Koth L, Wolters PJ, King TE, Jr. *Clinical, Physiologic, and Radiographic Comparison of Patients with Undifferentiated Connective Tissue Disease-ILD and Scleroderma-ILD.* Am J Resp Crit Care Med. 2009 179: A4493
28. Wolters PJ, Marmai C, Kim KK, Sutherland RE, Matthay MA, and Chapman HA, *Human Alveolar Type II Cells Acquire Features of Mesenchymal Cells When Cultured on Fibronectin.* Am J Resp Crit Care Med. 2009 179: A4999.
29. Sutherland RE, Kim SS, Olsen JS, Salantes DB, Caughey GH, and Wolters PJ. *Dipeptidyl Peptidase I Controls Survival from Klebsiella Pneumonia Lung Infection by Processing Surfactant Protein D.* Am J Resp Crit Care Med. 2010 181: A4163.
30. Seeley EJ, Sutherland RE, and Wolters PJ. *Mast Cells Degranulate in Tissues Distant to the Primary Site of Infection During Septic Peritonitis.* Am J Resp Crit Care Med. 2010 181: A1434.
31. Cha SI, Chang CS, Lee JW, Matthay MA, Elicker BM, Jones KD, Collard HR, and Wolters P. *Lung Mast Cell Density Defines a Subpopulation of Patients with Idiopathic Pulmonary Fibrosis.* Am J Resp Crit Care Med. 2011 183: A2335.
32. Lee JS, Song JW, Wolters PJ, Elicker BM, King TE, Kim DS, and Collard HR. *Bronchoalveolar Lavage Pepsin Levels In Acute Exacerbation Of Idiopathic Pulmonary Fibrosis.* Am J Resp Crit Care Med. 2011 183: A3804.

33. Seeley EJ, Kim SS, Matthay MA, and Wolters PJ. *Endogenous Catecholamines Impair Innate Immune Responses and Worsen Survival During Septic Peritonitis in Mice*. Am J Resp Crit Care Med. 2011 183: A3852.
34. Burrell G, Mooney JJ, Ryu J, Ryerson C, Elicker B, Jones K, Wolters P, King T, Koth L, Collard HR, Lee JS. *The Relationship Of Body Mass Index To Survival Time In Interstitial Lung Disease*, Am J Resp Crit Care Med. 185 2012: A4120
35. Lee JS, Kim EJ, Lynch KL, Elicker B, Ryerson CJ, Katsumoto TR, Shum AK, Wolters PJ, Richeldi L, Jones KD, King TE, Collard HR. *Circulating Autoantibodies Are Associated With Longer Survival Time In Idiopathic Pulmonary Fibrosis*, Am J Resp Crit Care Med. 185 2012: A4372
36. Arron JR, Chandriani S, Abbas AR, Jackman J, Karnik S, Wu LC, Collard HR, and Wolters PJ. *IL4 And IL13 Induce GLI1 In Pulmonary Fibroblasts Via An IL4Ra/IL13Ra1-Dependent, Hh And TGF β -Independent Manner*, Am J Resp Crit Care Med. 185 2012: A4940
37. Jaffar J, Tan X, Black JL, Oliver BG, Corte T, Wolters P, Argraves WS, Twal WO, and Burgess JK. *The Serum Level Of Fibulin-1 Is Elevated In Idiopathic Pulmonary Fibrosis*. Am J Resp Crit Care Med. 185 2012: A5173
38. Cha SI, Schroeder A, Kukreja J, Jones K, Golden J, Matthay MA, Collard HR, Erle DJ, Wolters PJ. *Alveolar Epithelial Cells Express Markers Of Senescence In Lungs From Patients With Idiopathic Pulmonary Fibrosis*. Am J Resp Crit Care Med. 185 2012: A5281
39. Chen C, Kudo M, Atakilit A, Takano H, Wolters P, Huang X, Sheppard D. *Integrin α 9 β 1 In Airway Smooth Muscle Regulates A Novel Brake On Exaggerated Murine And Human Airway Narrowing*. Am J Resp Crit Care Med. 185 2012: A6675
40. Tatler AL, Saini G, Goodwin A, Gbolohan O, Clifford RL, Al'Hourani M, Porte J, Violette S, Weinreb P, Knox A, Laurent G, Wolters P, Gauldie J, Kolb M, and Jenkins G. *Transcriptional Mechanisms Regulating Expression of the Avb6 Integrin in IPF*. Thorax. 2012; 67: Suppl 2 A34-A35
41. Jaffar J, Unger S, Corte T, Wolters PJ, Richeldi L, Cerri S, Argraves WS, Oliver BG, Black JL, Burgess JK. *Levels Of Fibulin-1 In The Lung And Serum Are Increased In Fibrotic Interstitial Lung Disease*. Am J Respir Crit Care Med. 187 2013: A3382
42. Murphy E, Zhang W, Peljto AL, Brown KK, Steele MP, Loyd JE, Cosgrove GP, Lynch DA, Groshong SD, Collard HR, Wolters PJ, Bradford WZ, Kossen K, Seiwert SD, du Bois RM, Garcia CK, Devine MS, Gudmundsson G, Isaksson HJ, Kaminski N, Zhang Y, Gibson KF, Lancaster LH, Cogan JD, Mason WR, Maher TM, Molyneaux PL, Wells AU, Moffatt MF, Selman M, Pardo A, Kim DS, Crapo JD, Make BJ, Regan EA, Walek DS, Daniel JJ, Kamatani Y, Zelenika D, Smith K, McKean D, Pedersen BS, Talbert

- J, Kidd RN, Markin CR, Beckman KB, Lathrop M, Schwarz MI, MD¹, Schwartz DA. *Novel Genetic Risk Loci For Pulmonary Fibrosis*. Am J Respir Crit Care Med. 187 2013: A6058
43. Tatler, AL, Goodwin A, Porte J, Clifford RL, Weinreb P, Violette S, Gauldie J, Kolb MRJ, Parfrey H, Wolters PJ, Laurent G, Jenkins GR. *Multiple Mechanisms Regulating Enhanced Expression Of $\alpha\text{v}\beta\text{6}$ Integrins In Pulmonary Fibrosis*. Am J Respir Crit Care Med. 187 2013: A5142
 44. Lee JS, Collard HR, Elicker B, Jones KD, King TE, MD, Wolters PJ. *Telomere Length And Survival In Idiopathic Pulmonary Fibrosis*. Am J Respir Crit Care Med. 187 2013: A5715
 45. Connolly, MK, Katsumoto T, Wolters P, Cleveland C, Herrera B, Tang P, Mathauda S, Lao R, Kwok PY, and Criswell LA. *Exome Sequencing For Identification Of Potential Causal Variants For Diffuse Cutaneous Systemic Sclerosis*. Arthritis Rheumatol. 2013: 65, S61-S61.
 46. Kern R, Singer J, Koth L, Mooney M, Golden G, Wolters P, Hays S, Ghio E, Kukreja J, Blanc P. *Lung Transplantation for Hypersensitivity Pneumonitis*. J Invest Med. 2014 62:183.
 47. Assayag D, Vittinghoff E, Ryerson CJ, Tonelli R, Cocconcelli E, Elicker B, Golden J, Jones KD, King TE, Koth LL, Lee JS, Ley B, Wolters PJ, and Collard HR. *The Effect Of Bronchodilators On Forced Vital Capacity In Patients With Idiopathic Pulmonary Fibrosis*. Am J Respir Crit Care Med. 2014: A1433.
 48. Johansson KA, Elicker B, Vittinghoff E, Jones KD, Lee JS, Wolters PJ, Golden J, Koth LL, and Collard, HR. *A Clinical Model Can Accurately Predict A Diagnosis Of Chronic Hypersensitivity Pneumonitis*. Am J Respir Crit Care Med. 2014: A6583.
 49. Assayag D, Kim E, Elicker B, Golden J, Jones KD, King TE, Koth LL, Wolters PJ, Collard HR and Lee JS. *Survival In Interstitial Pneumonia With Features Of Autoimmune Disease*. Am J Respir Crit Care Med. 2014: A1484.
 50. Tatler AL, Goodwin A, Porte J, Gbolahan O, Clifford RL, Weinreb P, Violette S, Gauldie J, Kolb MR, Parfrey H, Wolters PJ, Laurent G, and Jenkins G. *Identification Of A Novel Region Of The ITGB6 Promoter Responsible For Basal Repression Of ITGB6 Transcription And Therefore $\alpha\text{v}\beta\text{6}$ Expression*, Am J Respir Crit Care Med. 2014: A3436.
 51. Disayabutr S, Bhakta N, Ley B, Papa F, Lee JS, MD, Collard HR, and Wolters PJ. *MicroRNA-17 Is A Biomarker Of ER-Stress In Idiopathic Pulmonary Fibrosis Patients*, Am J Respir Crit Care Med. 2014: A3927.
 52. Kennedy GC, Wilde JI, Velichko S, Diggans J, Kim SY, Kumm J, Tom E, Sindy N, L. Friedman L, Colby TV, Myers JL, Katzenstein A, Lynch DA, Steele MP, Flaherty KR,

- Brown KK, Pardo A, Selman M, Wolters PJ, Nathan SD, and Lanman RB. *Diagnosis Of Interstitial Lung Diseases Using Machine Learning On High-Dimensional Transcriptional Data And Pathological And Clinical Assessment*, Am J Respir Crit Care Med. 2014: A3930
53. Kern RM, Singer JP, Koth LL, Mooney J, Golden J, Hays S, Wolters PJ, Ghio E, Kukreja J, and Blanc PD. *Lung Transplantation For Hypersensitivity Pneumonitis*. Am J Respir Crit Care Med. 2014: A5172.
 54. Fingerlin TE, Zhang W, Peljto AL, Murphy E, Brown KK, Steele MP, Loyd JE, Cosgrove GP, Lynch DA, Groshong SD, Collard HR, Wolters PJ, Bradford WZ, Kossen K, Seiwert SD, Du Bois RM, Garcia CK, Devine M, Gudmundsson G, Isaksson HJ, Kaminski N, Zhang Y, Gibson KF, Lancaster LH, Cogan JD, Mason WR, Maher TM, Molyneaux PL, Wells AU, Moffatt MF, Selman M, Pardo A, Kim DS, Crapo J, Make BJ, Regan EA, Walek DS, Daniel JJ, Kamatani Y, Zelenika D, Smith K, McKean D, Pedersen B, J, Kidd RN, Markin CR, Beckman KB, Lathrop M, Schwarz MI, Schwartz DA. *Genome-wide Imputation Study Identifies New Genetic Loci For Pulmonary Fibrosis*, Am J Respir Crit Care Med. 2014: A5263.
 55. Peljto A, Selman M, Kim DS, Tucker L, Murphy E, Zhang W, Brown KK, Steele MP, Loyd JE, Cosgrove GP, Lynch DA, Groshong SD, Collard HR, Wolters PJ, Bradford WZ, Kossen K, Seiwert SD, Du Bois RM, Garcia CK, Devine M, Gudmundsson G, Isaksson HJ, Kaminski N, Zhang Y, Gibson KF, Lancaster LH, Cogan JD, Mason WR, Maher TM, Molyneaux PL, Wells AU, Moffatt MF, Pardo A, Crapo J, Make BJ, Regan EA, Walek DS, Daniel JJ, Kamatani Y, Zelenika D, Smith K, McKean D, Pedersen BS, Talbert J, Kidd RN, Markin CR, Beckman KB, Lathrop M, Schwarz MI, Yang IV, Fingerlin T, Schwartz DA. *Genetic Variants Associated With Pulmonary Fibrosis In Asian And Hispanic Populations*. Am J Respir Crit Care Med. 2014: A5568.
 56. Wang P, Jones KD, Urisman A, Collard HR, Johannson KA, Wolters PJ, Assayag D, Elicker B, Urbania T, and Koth LL. *Chronic Hypersensitivity Pneumonitis: Distribution Of Pathological Patterns In A Large Prospective Cohort*, Am J Respir Crit Care Med. 2014: A6402.
 57. Jia G, Chandriani S, Abbas AR, DePianto D, N'Diaye E, Yaylaoglu M, Collard HR, Wolters P, Egen J, Scalori A, Ackrill A, Hou J, Kaminski J, Maher TM, and Arron JR. *Target And Biomarker Discovery For Hedgehog Pathway Activity In Idiopathic Pulmonary Fibrosis In Support Of A Phase 2 Randomised, Double-blind, Placebo-controlled Study To Assess Efficacy And Safety Of Vismodegib In IpF (island)*. Thorax. 2014; 69: Suppl 2 A87.
 58. Greenland JR, Wong CM, Ahuja R, Uchida C, Golden J, Hays SR, Leard LE, Singer JP, Kukreja J, Wolters PJ, Caughey GH, and Tang Q. *Depletion Of Donor-Reactive Regulatory T Cells Following Induction With Basiliximab*, Am J Respir Crit Care Med. 2015: A62487.

59. Lee JS, Wolters PJ, Cello JP, Golden J, Aziz S, Jones KD, Rogers S, Matthay MA, King TE, and Collard HR. *Bronchoalveolar Lavage Pepsin Levels Are Significantly Elevated In Patients With Idiopathic Pulmonary Fibrosis*. Am J Respir Crit Care Med. 2015: A65210.
60. Naikawadi RP, Disayabutr S, Mallavia B, Donne M, Green G, Rock JR, Looney MR, and Wolters PJ. *Telomere Dysfunction in Alveolar Epithelial Cells Causes Pulmonary Fibrosis*. Am J Respir Crit Care Med. 2016: A2392.
61. Faust HE, Rajalingam R, Wolters PJ, Singer JP, Wang A, Green G, Golden JA, Hays S, Kukreja J, and Greenland JR. *Decreased Telomere Lengths in Lung Transplant Recipients Relative to Donors*. Am J Respir Crit Care Med. 2016: A3453.
62. Moermans C, Lou H, Brand OJ, Cormier A, Bondesson A, Wolters PJ, Jablons D, Murray L, and Nishimura S. *The Relative Importance of α -Integrins in Chronic Obstructive Pulmonary Disease*. Am J Respir Crit Care Med. 2016: A1423
63. Morisset J, Vittinghoff E, Lee B, Tonelli R, Hu X, Elicker BM, Ryu JH, Jones KD, Cerri S, Manfredi A, Sebastiani M, Ley BJ, Wolters PJ, King TE, Kim D, Collard HR, and Lee JS. *Predicting Mortality in Patients with Rheumatoid Arthritis Related Interstitial Lung Disease: Expanding The GAP Model*. Am J Respir Crit Care Med. 2016: A4288.
64. Faust HE, Golden JA, Rajalingam R, Wang AS, Green G, Hays S, Kukreja J, Singer JP, Wolters PJ, and Greenland JR. *Decreased Donor PBMC and Allograft Telomere Length Are Associated with Shorter CLAD-Free Survival*. J Heart Lung Transplant. 2017; 36: S129–S130.
65. Lee, JS, Deane, KD, Walts AD, Fingerlin TE, Fischer A, Ryu J, Matteson EL, Niewold TB, Assayag D, Wolters PJ, Collard HR, Schwarz MI, Holers VM, and Schwartz DA. *The MUC5B Promoter Variant Is Associated With Rheumatoid Arthritis Associated Interstitial Lung Disease*. Am J Respir Crit Care Med. 2017; 195: A2456.
66. Ley B, Newton CA, Arnould I, Elicker BM, Henry TS, Jones KD, Garcia CK, and Wolters PJ. *The Muc5b Promoter Polymorphism And Shorter Telomere Length Are Associated With Idiopathic Pulmonary Fibrosis-Like Features In Chronic Hypersensitivity Pneumonitis*. Am J Respir Crit Care Med. 2017; 195: A7415.
67. Walker TD, de Andrade JA, Bendstrup E, Blackwell TS, Borie R, Brown KK, Christie JD, Collard HR, Corte TJ, Crestani B, du Bois RM, Eickelberg O, Gibson KF, Henry M, Gudmundsson G, Hirani N, Inoue Y, Jenkins RG, Kass D, Kawut SM, Keane JM, Kim D, Laurent G, Lederer DJ, Loyd JE, Mogulkoc N, Molina-Molina M, Nathan S, Noth I, Ohta K, Parfrey H, Prele CM, Selman M, Song J, Sterclova M, Tobin MD, Vasakova M, Wolters PJ, Powers J, Waltz A, Schwarz MI, and Schwartz DA. *The Global Idiopathic Pulmonary Fibrosis (IPF) Collaborative Network: A Platform For IPF Genetics*. Am J Respir Crit Care Med. 2017; 195: A6794.

68. Singer JP, Soong A, Bruun A, Hays S, Kukreja J, Bracha A, Chin G, Wolters PJ, Peters M, and Garvey CM. *"pre-Habilitation" Of Frail Candidates For Lung Transplantation Using A Mobile Health Enabled Home-Based Intervention Is Feasible And Safe.* Am J Respir Crit Care Med. 2017; 195: A2342.
69. Johansson KA, Vittinghoff E, Morisset J, Wolters PJ, Noth EM, Balmes JR and Collard HR. *Air Pollution Exposure, Lung Function And Dyspnea In Patients With Idiopathic Pulmonary Fibrosis.* Am J Respir Crit Care Med. 2017; 195: A1126.
70. Flaherty KR, de Andrade JA, Chou W, Lancaster LH, Lindell KO, Nathan SD, Raghu G, Spino C, Stauffer JL, Tuomey P, Wolters PJ, and Cosgrove GP. *Baseline Characteristics Of The Initial 200 Participants In The Pulmonary Fibrosis Foundation Registry.* Am J Respir Crit Care Med. 2017; 195: A1132.
71. Lee JS, Ley BJ, Hennessy CE, Estralla A, Walts AD, Schwarz MI, Wolters PJ, Collard HR, Yang I, and Schwartz DA. *Idiopathic Pulmonary Fibrosis And The Muc5b Promoter Variant Rs35705950 Are Associated With Elevated Concentrations Of Muc5b In Bronchoalveolar Lavage Fluid.* Am J Respir Crit Care Med. 2017; 195: A6793.
72. Baluk P, Naikawaidi RP, Kim S, Wolters PJ, and McDonald DM. *Prolific lymphatic growth in mouse lungs after bleomycin-induced injury or lung-specific telomere dysfunction.* Barga Italy 2018.
73. Ley BJ, Liu S, Elicker BM, Henry TS, Vittinghoff E, Golden JA, Jones KD, and Wolters PJ. *Telomere Length and the MUC5B Promoter Polymorphism in Patients with Unclassifiable Interstitial Lung Disease.* Am J Respir Crit Care Med. 2018; 197: A43.
74. Decaris M, Pike I, Wolters PJ, Bremang M, Gaster R, Andre P, and Turner S. *Proteomic Analysis of Plasma and Tissue Samples for the Identification of Pharmacodynamic Biomarkers in IPF.* Am J Respir Crit Care Med. 2018; 197: A2232.
75. Juge P, Lee JS, Ebstein E, Furukawa H, Gazal S, Kannengiesser C, Tsuchiya N, Oka S, Tohma S, Rojas J, Serrano S, González-Pérez M, Mejía M, I. Buendia I, Falfan-Valencia R, Ambrocio-Ortiz E, Manali ED, Papiris A, Karageorgas T, Boumpas D, Antonio A, Van Moersel CH, van der Vis J, de Man Y, Grutters JC, Yaping W, Borie R, Wemeau-Stervinou L, Wallaert B, Nunes H, Valeyre D, Saindenberg N, Marchand Adam S, Deane K, Walts AD, Fingerlin TE, Fischer A, Ryu JH, Matteson EL, Niewold T, Assayag D, Gross AJ, Wolters PJ, Schwarz MI, Solomon J, Doyle TJ, Marie-Pierre D, Boileau C, Schwartz DA, Crestani B, and Philippe D; *The Common Gain-of-function MUC5B Promoter Variant rs35705950 Contributes to the Risk of Developing Rheumatoid Arthritis Interstitial Lung Disease.* Am J Respir Crit Care Med. 2018; 197: A2292.
76. Raghu G, Pellegrini C, Yow ES, Flaherty KR, Meyer KC, Noth I, Scholand M, Cello J, Ho LA, Lee JS, Lin J, Maloney P, Martinez FJ, Morrow E, Patti M, Rogers S, Wolters PJ, Yates R, Anstrom K, and Collard HR; *A Phase 2 Randomized, Controlled*

Trial of Laparoscopic Anti-Reflux Surgery for the Treatment of Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2018; 197: A7698.

77. Liu S, C. Wang C, Green G, Calfee CS, Ware LB, and Wolters PJ; *Peripheral Blood Leukocyte Telomere Length Predicts Survival in Critically Ill Patients: An Observational Cohort Study.* Am J Respir Crit Care Med. 2018; 197: A4174
78. Naikawadi RP, Green G, and Wolters PJ; *Telomere Dysfunction in Clara Cells Leads to Airway-Centric Lung Remodeling and Fibrosis.* Am J Respir Crit Care Med. 2018; 197: A4646.
79. Walker T, D. Schwartz DA, Schwarz MI, Fingerlin TE, Powers J, De Andrade JA, Bendstrup E, Blackwell TS, Borie R, Brown KK, Christie JD, Collard HR, Corte TJ, Crestani B, Eickelberg O, Gibson KF, Gudmundsson G, Henry M, Hirani N, Inoue Y, Jenkins RG, Kass D, Kawut SM, Keane JM, Kennedy MP, Laurent GJ, Lederer DJ, Loyd JE, Mogulkoc N, Musani AI, Molina J, Nathan SD, Noth I, Ohta K, Parfrey H, Poletti V, Prele C, Ryerson CJ, Selman M, Shea B, Song J, Steele MP, M. Sterclova M, Tobin MD, Tomassetti S, Vasakova M, Waltz A, Wolters PJ, and Zhang Y; *An Update on the Global Idiopathic Pulmonary Fibrosis (IPF) Collaborative Network: A Platform for IPF Genetics.* Am J Respir Crit Care Med. 2018; 197: A5755.
80. Pike I, Bremang M, Wolters PJ, Gaster R, Turner S, and Decaris M. *A Novel Method for Discovery of Peripheral Blood Biomarkers in Idiopathic Pulmonary Fibrosis Using Extensive Depletion and TMT calibrator Tissue-Enhanced Plasma Proteomics.* Am J Respir Crit Care Med. 2018; 197: A5771.
81. Morisset J, Johannson KA, Jones KD, Wolters PJ, Collard HR, Walsh SLF, and Ley B. *Identification of Diagnostic Criteria for Chronic Hypersensitivity Pneumonitis: An International Modified Delphi Survey.* Am J Respir Crit Care Med. 2018; 197: A6182.
82. Flaherty K, De Andrade J, Lancaster L, Limb S, Lindell K, Nathan S, Raghu G, Spino C, Stauffer J, Wolters P, and Cosgrove. *Baseline characteristics of 1461 participants in the Pulmonary Fibrosis Foundation Patient Registry.* Eur Resp J. 2018; A2199.
83. Zhang Y, Jones K, Achar-Zadeh N, Kukreja J, and Wolters P. *Histopathologic and Molecular Analysis of Idiopathic Pulmonary Fibrosis Lungs from Patients Treated with Pirfenidone or Nintedanib.* Eur Resp J. 2018; A2920.
84. Lee J, Dobrinskikh E, Estrella A, Schulick A, Yang I, Wolters P, and Schwartz D. *MUC5B is expressed by bronchoalveolar epithelia and is associated with ER stress in idiopathic pulmonary fibrosis and rheumatoid arthritis associated interstitial lung disease.* Eur Resp J. 2018; A3711.
85. Lee J, La J, Aziz S, Brownell R, Jones K, Green G, Elicker B, Golden J, Matthay M, Kukreja J, Collard H, and Wolters P. *Molecular Markers of Telomere Dysfunction and Senescence are Common Findings in the Usual Interstitial Pneumonia Pattern of Lung Fibrosis.* Eur Resp J. 2018; A5362.

86. Decaris M, Rexhepaj M, Vowinckel J, Dupuis N, Wei Y, Hariri LP, Greenland JR, H. A. Chapman HA, Lee JS, Wolters PJ, and Turner S. *Urine Proteomics Identifies Novel Biomarkers of IPF Disease Progression and Resolution*. Am J Respir Crit Care Med. 2019; A1238.
87. Dvorkin D, Fischer A, Achta-Zadeh N, Wolters PJ, and Lee JS. *Biomarkers in Systemic Sclerosis Associated Interstitial Lung Disease*. Am J Respir Crit Care Med. 2019; A1432
88. Wang C, Wolters PJ, Calfee CS, Liu S, Balmes JR, Koyama T, Zhao Z, and Ware LB. *Long-Term Ozone and PM_{2.5} Exposure Is Positively Associated with Telomere Length in Critically Ill Patients*. Am J Respir Crit Care Med. 2019; A2396.
89. Furusawa H, Cardwell J, Okamoto T, Walts AD, Schwarz MI, Cool CD, Wolters PJ, Lee JS, Yang IV, and Schwartz DA. *Chronic Hypersensitivity Pneumonitis (CHP), an ILD with Distinct Molecular Signatures*. Am J Respir Crit Care Med. 2019; A7343.
90. Matson S, Lee JS, W. Ren W, Collard HR, Matthay MA, Achta-Zadeh N, Wolters PJ, Hansen K, and Eickelberg O. *Common and Distinct Transcriptome and Proteome Expression Patterns from Lungs in Idiopathic Pulmonary Fibrosis (IPF) and Rheumatoid Arthritis-Associated Interstitial Lung Disease (RA-ILD)*. Am J Respir Crit Care Med. 2019; A5258.
91. Ley BJ, Torgerson DG, Oldham J, Adegunsoye AO, Liu S, Li J, Elicker BM, Henry TS, Golden JA, Jones KD, Yaspan BL, Arron JR, Noth I, Hoffmann T, and Wolters PJ. *Rare Protein-Altering Telomere-Related Gene Variants in Patients with Chronic Hypersensitivity Pneumonitis: An Observational Cohort Study*. Am J Respir Crit Care Med. 2019; A5842.
92. Cerani A, Ross S, Schwartz DA, Wolters P, and Richards B. *A metabolic biomarker for idiopathic pulmonary fibrosis: a two sample Mendelian randomization study and a case-control study*. Eur J of Human Genetics. 2019; 27: 84.
93. Maheshwar J, Kolaitis NA, Anderson MR, Benvenuto L, Gao Y, Katz P, Wolters P, Golden J, Kukreja J, Hays SR, Greenland JR, Shah R, Leard LE, Trinh B, Oyster M, Covinsky K, Calabrese D, Venado A, Patel P, Huang C, Glidden D, Kleinhenz M, N. Sutter N, Tietje-Ulrich G, Brown M, Arcasoy S, Christie JD, Diamond J, and Singer JP. *Sarcopenia is Associated with Frailty in Lung Transplant Candidates*. J Heart Lung Transplant. 2020
94. Yang IV, Cardwell J, Zhang W, Borie R, Walts A, Powers J, Rojas M, Wolters PJ, Fingerlin TE, and Schwartz DA. *Functional Validation of MUC5B and DSP Genetic Variants in Idiopathic Pulmonary Fibrosis (IPF) by Expression Quantitative Trait Locus (EQTL) and Co-Localization Analyses*. Am J Respir Crit Care Med 2020; 201: A2256.

95. Neighbors M, Sheng XR, Belloni P, Coimbra AF, Cheung DS, Burgess T, Goldin J, Kim GH, Guquan J, Morshead K, DePianto D, Wolters PJ, and Ramalingam T. *Correlation of HRCT Features with Peripheral Blood Biomarkers CXCL13 and MMP7 in Two Idiopathic Pulmonary Fibrosis Clinical Trial Cohorts.* Am J Respir Crit Care Med 2020; 201: A4038.
96. Tsukui T, Sun K-H, Wilson-Kanamori JR, Wetter JB, Hazelwood LA, Henderson NC, Matthay MA, Wolters PJ, and Sheppard D. *Identification of Pathologic Fibroblasts with the Highest Level of ECM Gene Expression and Migratory Phenotype in Pulmonary Fibrosis.* Am J Respir Crit Care Med 2020; 201: A2510.
97. Liu S, Ley B, French S, Elicker B, Chung MP, Fiorentino DF, Chung LS, Boin F, and Wolters PJ. *Peripheral Blood Leukocyte Telomere Length Predicts Progression of Interstitial Lung Disease Associated with Systemic Sclerosis: Longitudinal Analysis of an Observational Cohort Study with Independent Validation.* Am J Respir Crit Care Med 2020; 201: A1086.
98. Matson S, Cardwell J, Yang IV, Deane K, Ryu JH, Matteson E, Wolters PJ, Schwartz DA, and Lee JS. *Circulating Protein Biomarkers in Rheumatoid Arthritis Associated Interstitial Lung Disease.* Am J Respir Crit Care Med 2020; 201: A1094.
99. Venado A, Dewey K, Montas G, Greenland J, Leard L, Shah R, Kolaitis N, Calabrese D, Kleinhenz M, Kukreja J, Wolters P, Singer J, Golden J, and Hays S. *Safety and Tolerability of Pirfenidone for Restrictive Chronic Lung Allograft Dysfunction (PIRCLAD): Interim Results.* Chest 2020; 158: A2389-A2390.
100. Venado A, Montas G, Dewey K, Singer J, Calabrese D, Kolaitis N, Leard L, Shah R, Kleinhenz M, Kukreja J, Wolters P, Golden J, and Hays S. *Lung Function Trajectory in the Pirfenidone for Restrictive Chronic Lung Allograft Dysfunction (PIRCLAD) Trial: interim analysis.* Chest 2020; 158: A2391-A2392.
101. Konigsberg IR, Borie R, Cardwell J, Walts A, Powers J, Brancato J, Rojas M, Wolters PJ, Brown KK, Blackwell TS, Fingerlin TE, Schwartz DA, and Yang IV. *A Multi-Omic Approach to Understanding the Molecular Landscape of IPF.* Am J Respir Crit Care Med 2021; 203: A4249.
102. Furusawa H, Cardwell JH, Peljto AL, Walts AD, Bang TJ, Cool CD, Lee JS, Wolters PJ, Yang IV, and Schwartz DA. *Common Idiopathic Pulmonary Fibrosis (IPF) Genetic Variants Are Associated with Chronic Hypersensitivity Pneumonitis (CHP).* Am J Respir Crit Care Med 2021; 203: A3143
103. An MC, Ho S, Rao V, Wolters P, Turner S, Schaub J, Decaris M. *Therapeutic Biomarker Discovery in Idiopathic Pulmonary Fibrosis (IPF) Through Proteomic Analysis of Precision-Cut Lung Slice (PCLS) Supernatants.* Am J Respir Crit Care Med 2022; 205: A4708
104. Budi E, Kotak P, Ho S, Rao V, Chen C, Wolters P, Schaub J, Turner S, and Decaris M. *Pharmacological Inhibitors of Integrin $\alpha\beta6$ That Differentially Modulate Protein*

Conformation Are Similarly Effective at Inhibiting Transforming Growth Factor Beta (TGF- β) Signaling in the Fibrotic Lung. Am J Respir Crit Care Med 2022; 205: A5235

105. Hu X, Kim J, Ma SF, Huang Y, Oldham J, Allen R, Molyneaux PL, Joseph C, Guillen Guio B, Hernández Beefink T, Kropski J, Lee CT, Adegunsoye AO, Pugashetti JV, Linderholm A, Streck ME, Hubbard RB, Hart SP, Nicholson A, Lancaster L, Lorenzo-Salazar JM, Vo V, Hirani N, Whyte MK, Parfrey H, Rassl D, Wallace W, Valenzi E, Zhang Y, Stockwell A, Kaminski N, Wolters PJ, Molina-Molina M, Martinez FJ, Hall IP, Tobin MD, Maher TM, Blackwell TS, Yaspan BL, RG Jenkins RG, Wain LV, Flores C, Noth I, and Manichaikul A. *Integrating Gene Expression with Genome-Wide Association Summary Statistics to Identify Genes Associated with Idiopathic Pulmonary Fibrosis Survival.* Am J Respir Crit Care Med 2022; 205: A2326

Book Chapters

1. Wolters PJ, Matthay MA. *Pulmonary Artery Catheterization: Indications.* In: Tobin MJ, ed. Principles and Practice of Critical Care Monitoring. New York City: McGraw-Hill, Inc. Health Professions Division; 1997. p. 763-771
2. Cohen M, and Wolters PJ. *Interaction between Epithelial and Mesenchymal Cells in Interstitial Lung Disease.* In: Encyclopedia of Respiratory Medicine, 2nd Edition; 2020

Other Publications (Editorials, letters, case reports, multimedia)

1. Wolters PJ. *Could N-Acetylcysteine Slow Progression of Idiopathic Pulmonary Fibrosis by Inhibiting EMT?* Am J Physiol Lung Cell Mol Physiol. 2009; 297: L803-4.
2. Wolters, PJ. *Update on the Diagnosis and Management of Interstitial Lung Diseases.* Audio-Digest Internal Medicine. 2010. Volume 57 Issue 20.
3. Johansson KA, de Boer K, Wolters PJ, Golden JA, Lee JS, Collard HR. *Correspondence Re: Diagnosis of idiopathic pulmonary fibrosis with high-resolution CT in patients with little or no radiographic evidence of honeycombing: secondary analysis of a randomized clinical trial.* Lancet Resp Med 2014; 2: e5.
4. Wolters PJ and Elicker BM. *Subacute onset of Pulmonary Langerhans' - Cell Histiocytosis With Resolution after Smoking Cessation.* Am J Resp Crit Care Med 2014; 190: e64.
5. Wolters PJ. *A Recurring Theme in Pulmonary Fibrosis Genetics.* Eur Resp J 2017 49: 1700545 [https://doi.org/10.1183/13993003.00545-2017].
6. Johansson KA, Vittinghoff E, Morisset J, Wolters PJ, Noth EM, Balmes JR, and Collard HR. *Response to Sese et al re: Impact of Particulate Matter on the Natural History of IPF.* Chest. 2018; 154: 727-728.

7. Wolters PJ. *The Role of Aging and Senescence in Idiopathic Pulmonary Fibrosis*. Chest. 2018; Supplement: 8-9.
8. Tzouvelekis A and Wolters PJ. *Pirfenidone in the kaleidoscope: reflecting mechanisms through different angles*. Eur Respir J. 2018; 52: 1802046 [<https://doi.org/10.1183/13993003.02046-2018>].
9. Wolters PJ and Cottin V. *Molecular Endpoints for Establishing Target Engagement by Novel Idiopathic Pulmonary Fibrosis Therapies*. Eur Respir J. 2019; 53: 1900283 [<https://doi.org/10.1183/13993003.00283-2019>].
10. Venado A, Witt LJ, Kallianos K, and Wolters PJ. *Diaphragmatic Atrophy May Limit Progression of Idiopathic Pulmonary Fibrosis*. Am J Respir Crit Care Med. 2020; 201: e72-e73.
11. Naikawadi R and Wolters, PJ. *MAV(S)erick mitochondria: An unconventional role for mitochondrial antiviral signaling protein in Pulmonary Fibrosis*. Eur Respir J. 2021; 57: 2004500
12. Collard HR and Wolters PJ. *Where Is Idiopathic Pulmonary Fibrosis Treatment Going?* 2021; Medscape, WebMD.
13. Yang MM and Wolters PJ. *Cut From the Same Cloth: Similarities Between Hypersensitivity Pneumonitis and IPF*. Am J Respir Crit Care Med. 2022; 205: 4-6.